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1 Introduction 
 
1.1 Transcript therapy 
 
“Gene therapy uses the nucleic acids as medicine to cure genetic deficiencies and a 
large variety of acquired diseases”, according to Midoux et al. (2009, p.166) [1]. The 
related and more progressive approach of transcript therapy however does not cure 
diseases but treats the symptoms by adjusting and interfering with pathways in protein 
production. Transcript therapy is defined as the utilization of single-stranded 
ribonucleic acids as a therapeutic agent and contains many forms of ribonucleic acids 
like, small interfering RNA (siRNA) and messenger RNA (mRNA). These different 
forms of transcripts are all desired to be introduced into cells, without being 
metabolized and damaged before they arrive at the site of interest. Even though 
polycations were the first agents used for introducing nucleic acids into cells, the later 
developed recombinant viral vectors have been far more efficient in doing so. These 
vehicles have already proven their functionality to treat some diseases where classic 
“small molecule” medicine reached its limits, but the side-effects often outweigh their 
potential, like i.e. insertional mutagenesis or immunogenicity [2, 3]. Hence, the search 
for novel innovative carrier systems especially in transcript therapy is one of the 
imminent challenges, where basically parts of the main strategy of viruses is tried to 
be imitated. For successful applications where nucleic acids are the therapeutic agent, 
the protection of the cargo, trespassing the cell wall, the transfer into the cytosol and 
in the case of DNA into the nucleus, are necessary steps [1]. The mere fact that up to 
2400 different therapeutic nucleic acid clinical trials were ongoing or approved 
worldwide until mid of 2016 is just an indicator how contemporary this field of research 
is at the moment and how important progress in the development of appropriate carrier 
systems for these therapeutic approaches are [4, 5]. 
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1.1.1 Chemically modified messenger RNA 
 
As protein therapy comes with adverse effects like a lack of stability in vivo, and an 
often too complex chemical structure for synthetic development and carrier system 
development, the idea of letting the body produce its own therapeutic via transcript 
therapy emerged. Plasmid DNA transfection and the direct introduction into the 
genome comes with the danger of mutagenesis which makes it a risky alternative for 
protein therapy, as well. Also, as the transport into the nucleus only happens during 
cell division, plasmid DNA as a therapeutic tool only makes sense in dividing cells in 
general. Here, the introduction of transcript therapy and messenger RNA delivery in 
special, which is not being internalized into the genome and solely translated in the 
cytosol, could be one of the most promising candidates for treating patients with gene 
defects [6, 7]. 
One of the most challenging obstacles for using mRNA as a therapeutic agent is the 
immune system. Immunogenicity and stability from the application to translation have 
so far been the major obstacles to be overcome in mRNA therapy research, especially 
for getting into clinical trials [8]. The innate immune system is trained by evolution to 
detect foreign nucleic acids and protect cells from those, to enter via pattern recognition 
of i.e. toll-like receptors (TLR). The activation of TLRs leads to production of mainly 
interferons and pro-inflammatory cytokines [9]. Furthermore, the existence of RNases 
in the blood stream and the cells hinder foreign mRNA from being translated, which is 
beneficial for health but a challenging task for therapeutic mRNA approaches [10]. 
Hence, the modification of single nucleosides was introduced which not only lowered 
the immune response but had the potential of increasing the translation potential. 
Chemical modifications like pseudouridine, 2-thiouridine (Scheme 1) or methyl-cytidine 
have proven to lower response by TLRs significantly [11]. 
By the incorporation of a certain ratio of chemical modifications to nucleosides without 
changing the protein encoding parts in mRNAs, the therapeutic window gets widened 
by lowering the immune system’s ability to detect the product before it gets translated 
[6, 11, 12]. 
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Scheme 1 - Exemplary modification scheme of A) uridine to B) 2-thio-uridine. By exchanging the oxygen 
with sulphur on position 2 of the phenyl group, the activation of the immune system is lowered [13]. 
 
1.2 cmRNA as a therapeutic tool 
 
Chemically modified RNA has been of interest in clinical and non-clinical trials for the 
last years in several different research groups placed around the globe. Kormann  
et al. i.e. succeeded in the in vivo translation of erythropoietin (EPO) by cmRNA 
transfection and a subsequent substantial increase of hematocrit by a single 
intramuscular injection of EPO encoding cmRNA complexes in mice [6]. Another 
example would be the trials by Balmayor et al. where cmRNA encoding for bone 
morphogenic protein 2 (hBMP-2) was incorporated in scaffolds for bone defect filling. 
Here the authors could show that the internalization of cmRNA could even lead to 
faster bone growth [14]. Even in the delicate field of cardiology cmRNA technology was 
introduced as Abraham et al. showed that cmRNA containing stent coatings could 
potentially protect patients against angioplasty associated complications in 
atherosclerotic blood vessels [15]. These are just a few examples for fields in medicine 
where cmRNA could have a substantial impact in a near future. It also already hints at 
the potential of such nucleic acids to be used in a wide range of unrelated fields of 
applications.  
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1.3 Challenges in nucleic acid delivery 
 
As already mentioned nucleic acid delivery comes with certain challenges as the 
macromolecules need to be delivered to the interior of the target cell. In many cases, 
this task could not be overcome by non-viral vectors which led to employing viral 
vectors despite their enormous safety concerns [16, 17]. Furthermore, even though 
many different delivery agents have been developed over the last decades for an in 
vitro environment, an overwhelming majority of those agents lacked in efficiency in in 
vivo situations [18]. The most used carrier systems in nucleic acid delivery are cationic 
liposomes and polymers, as both families bind and complex nucleic acids via 
electrostatic interactions with negatively charged phosphodiester backbones [19].  
 
 
1.4 Delivery systems for nucleic acids 
 
Nucleic acids are considered robust macromolecules but the presence of nucleases in 
vivo and their poor cellular uptake imply the need for compacting agents which serve 
as a delivery mediator. Although there are some established physical delivery 
application routes like magnetofection [20] or the “gene gun” technology (gold particle 
bombardment) [21], chemical carrier systems like cationic lipids or polymers are often 
preferred. The requirements for an appropriate synthetic delivery system for nucleic 
acids in general are besides high functionality, the ability to compact the cargo, shield 
the negative charge and to transport the therapeutic agent to its target. Furthermore, 
as already mentioned, toxicity, immunogenicity and the potential to be repeatedly 
administered play major roles in the task to open the therapeutic window as wide as 
possible [22, 23]. Consequently, synthetic approaches which mimic viral features are 
desired in which functionality can be maintained while immune response and toxicity 
are reduced [4]. Understanding the pathway of nucleic acid delivery in general is crucial 
for the development of applicable delivery agents. The first hurdle is the plasma 
membrane, which is a barrier designed for lipophilic macromolecules, where the 
complex needs to bind to the cell surface before being internalized [24]. The pathway 
described mainly for polyplex- or lipoplex mediated cell uptake is endocytosis where 
extracellular macromolecules are internalized via vesicles which are basically pinched 
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off parts of the cell membrane (Scheme 2) [25]. The binding or docking to the cellular 
membrane can be achieved via unspecific charge interaction between carrier and 
extracellular matrix or ligand-receptor mediated binding. This pathway is common for 
mammalian cells and normally occurs for the internalization of essential nutrients, 
growth factors, antigens, and cholesterol-loaded lipoprotein for example. If a carrier 
successfully binds to receptors and the clathrin-coated vesicles (CCVs) are fused to 
endosomes, these have to be ruptured before being lysed or transported back to the 
cell membrane [26]. As the pH-level drops in endosomes, the carrier system’s escape 
can be triggered by i.e. fusogeneic lipids like DOPE which change their physiology pH-
dependently and destabilize the endosomal membrane [27]. Furthermore, the so-
called proton sponge effect was proposed especially for polymer-based carriers like 
polyethyleneimine (PEI) where the theory suggests that i.e. PEI gets protonated at 
lower pH levels, which triggers influx of ions like Cl- in combination with water, which 
swells the endosome until it bursts. Once released from the endosome and detached 
from their complexing agent, nucleic acids can be translated in the cytosol or even 
transferred into the nucleus (DNA) [28]. 
 
 
Scheme 2 – Transfection scheme for a PEI-nucleic acid complex. Cell uptake leads to encapsulation in the 
endosome which is followed by a pH-level drop. Via osmotic effects the endosome swells to a critical point 
where the endosome ruptures and releases the cargo [29]. 
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1.4.1 Polyplexes in nucleic acid delivery 
 
Polymer-based nucleic acid delivery has been investigated over the last 50 years. 
Cationic proteins which enhanced the infectivity of poliovirus RNA in the 1960s [30] or 
transfection complexes containing polyornithine and DNA which were first described 
in the 1970s [31] were the beginnings of exploiting the possibilities of cationic polymers. 
Over the years many different carrier systems based on this technology were 
introduced, including polymerosomes, polymer micelles, hydrogels and cationic 
polymers (polyplexes) [32]. All of these carrier systems form carrier families which have 
favorable application sites [33]. Pulmonary applications i.e. where surfactants play a 
major role extracellularly on the endothelial cells, provides an environment where 
liposome-mediated delivery is hindered [34]. Therefore, although lipoplex formulations 
tend to be more efficient in vitro, polymers as condensing agents are still relevant for 
several application routes in vivo. Furthermore, polymers used for nucleic acid 
transfection usually are able to condense their cargo more than lipid-based 
formulations which can lead to increased stability [24]. Generally, most of the polymers 
which have been successfully used in nucleic acid delivery bear free amines, which 
can be protonated in their structure. Prominent examples for polymer-based nucleic 
acid complexation agents are linear and branched PEI, polylysine, and biopolymers 
like chitosan or poly(lactic-co-glycolic acid) (PLGA) [33]. The transfection efficiency of 
polyplexes can be affected by the ratio of positive charges of the polymers, to negative 
charges of the nucleic acid’s backbone (nitrogen (N)/phosphate (P) ratio) as positively 
charged complexes with free amines can interact with the anionic extracellular matrix. 
However, it was observed that an increasing amount of free cationic polymer leads to 
higher cytotoxicity which limits its applicability. These attributes lead to a specific 
therapeutic window which differs for each nucleic acid type and complexing polymer 
[35]. The endosomal escape or release of polymer-based transfection agents can 
additionally be enhanced by the addition of lysosomotropic agents like chloroquine, 
although in the case of PEI such agents are not needed as endosomal escape is 
triggered by the polymer itself. This may be due to their efficient endosomal escape 
via the controversially discussed proton-sponge effect [36].  
Chitosan as a complexing agent for nucleic acid delivery has proven its validity in 
various cases especially where mucus barriers have to be crossed before cell uptake. 
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These application routes include nasal, intratracheal, pulmonary and even oral 
application for nucleic acid delivery. Its deacetylated backbone reveals primary amines 
in each monomer which is perfectly fitting to interact with the phosphate backbone of 
nucleic acids (chemical structures are shown in Scheme 3) [37-39]. 
 
Scheme 3 - Deacetylation of chitin to chitosan leads to free primary amines which can be utilized for nucleic 
acid backbone binding [40]. 
 
PLGA as a nanocarrier on its own for nucleic acids gathered some attention, as well, 
but low encapsulation and transfection efficiency made them unattractive for various 
applications [41]. However the combination of the chitosan’s complexing capacity and 
biocompatibility paired with the colloidal stability contributed by PLGA made both 
polymers a highly promising choice for cmRNA complexation, as well [42]. 
 
 
1.4.2 Lipoplexes in nucleic acid delivery 
 
Lipid mixes containing nucleic acids are commonly denominated as lipoplexes where 
cationic lipids serve as the complexing agent. These lipids usually have a polar head 
group and one or various hydrophilic alkyl moieties. This surfactant-like structure forms 
molecules to carrier-vesicles in which the hydrophilic cargo can be entrapped [24]. The 
use of cationic lipids in transcript therapy goes back to researchers like Felgner [43] or 
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Wu [44] in the mid-1980s and have been one of the most favorable delivery agents for 
nucleic acids ever since. Similar to polyplexes the cationic lipid binds to the negatively 
charged nucleic acid backbone but it hardly ever is formulated alone.  
Helper lipids like i.e. dioleoylphosphatidylethanolamine (DOPE) are needed to 
enhance endosomal escape. It could be shown that DOPE is able to fuse with other 
lipids when pH levels are dropping, just as it is happening in the endosome [27]. In this 
environment DOPE can adopt hexagonal structures that disturb the endosomal 
membrane which among other factors like the buffering capacity of the lipoplex, 
enhances the endosomal escape [45]. Also, the trans-bilayer flip-flop of negatively 
charged phospholipids can detach the nucleic acid from the cationic lipids and release 
the cargo into the cytosol [46]. Recent investigations about the mechanisms 
concerning the endosomal escape showed that buffering capacity of the cationic lipid 
in the pH level area of the endosome plays a major role in functionality of lipo- or 
polyplexes, as well [47]. 
Furthermore cholesterol is used to enhance lipoplex structure stability in physiological 
fluids [48] and to enhance binding to the extracellular matrix via scavenger receptors 
[49]. The particle’s charge mainly determines the size as neutral particles tend to 
agglomerate due to hydrophobic interactions. On the contrary, highly negatively- or 
positively charged particles exhibit small mean hydrodynamic diameters. To enhance 
interaction with the extracellular matrix positively charged lipoplexes are needed but 
the necessary charge for cell attachment also increases unspecific binding and 
therefore limits the use in systemic administration [50]. Especially unspecific binding to 
negatively charged substances in the serum may lead to aggregation and 
subsequently clearance. A common strategy to overcome this is PEGylation. 
polyethylenglycol (PEG) bearing lipids can form a hydrophobic shielding layer on the 
surface of lipoplexes [51]. The composition of lipid mixes for nucleic acid delivery 
therefore requires fine-tuning for each and every application for each cargo [52].  
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1.4.3 Scaffolds for nano-carrier systems 
 
Tissue engineering is defined as “the application of the principles and methods of 
engineering and life sciences toward the fundamental understanding of structure-
function relationships in normal and pathological mammalian tissues and the 
development of biological substitutes that restore, maintain, or improve tissue function” 
[53]. The marriage of biosciences, engineering and clinical application synergistically 
has the goal to enhance grafts which are supposed to substitute tissues and organs. 
Scaffolds and grafts to replace skin, cartilage or bone tissue have already been 
successfully applied in clinical trials but structures like nerves, muscles, intestine or 
even blood vessels are desired, as well [54]. The combination of tissue engineering 
and transcript therapy could therefore be a powerful synthesis as surrounding cells 
around a graft or implant could be induced to differentiate to enhance tissue growth 
and scaffold replacement. Furthermore, such bio-functional implants have the potential 
to lower costs of therapy due to lower rehabilitation times.  
There are two types of scaffolds designed to incorporate nucleic acids. They are either 
designed to release the nucleic acid complexes at site after implantation or to keep the 
cargo on the surface of the graft [55]. Additionally scaffolds have been created which 
carry transfected progenitor cells into the implants’ surrounding areas which potentially 
regenerates lost tissue [56]. Hence, the approach of combining nucleic acid delivery 
with the possibility to load nanocarriers or already transfected cells to specific sites, 
where protein production of any kind could be enhanced, can be combined with the 
ability of the tissue graft to physically support and template new tissue formation [57]. 
One example for a tissue engineering product which could be functionalized by nucleic 
acid complexes is injectable calcium phosphate cements. Those present a promising 
alternative to polymer based bone filling products because of their similarity to 
endogenous bone and high biocompatibility [58].  
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1.5 Poly (lactic-co-glycolic acid) (PLGA)  
 
The copolymer poly(lactic-co-glycolic acid) or PLGA is one of the most investigated 
and versatile polymers in biomedical engineering mainly because of its biocompatibility 
and adjustable biodegradability in vivo. The versatility of the polymer is displayed best 
in the variety of its usage. In Scheme 4 the chemical structures of both monomers and 
the polymer is displayed. 
 
Scheme 4 – Chemical structure of poly(lactic-co-glycolic acid) (PLGA) co-block polymer and its pure 
constituents poly(glycolic-acid) (PGA) and poly(lactic-acid) (PLA) [59]. 
PLGA coatings, nano- or microparticles, implants or even as surgical thread are only 
a few examples where the intrinsic features of PLGA is beneficial [60-62]. 
Physicochemical features like biodegradation velocity or hydrophobicity can be 
adjusted by the molecular weight, the ratio of glycolic- to lactic acid monomers and by 
the choice of head-groups on the polymer ends. If used as a carrier device, release 
kinetics is substantially influenced by the pH-level of surrounding fluids, drug type and 
the method PLGA is being processed [63, 64]. For pharmaceutical purposes the main 
topic of interest is the adjustability of drug release profiles. Depending on the 
hydrophobicity and the choice of PLGA composition, there are generally three 
distinguished release profiles which all have their appropriate field of application. In 
Fig. 1 A, three characteristic release profiles are shown where drug release can exhibit 
one or multiple phases. Type I shows a steady and monophasic release behavior in 
contrast to Type II where an initial burst is schematically displayed, followed by a 
saturation plateau. Type III displays a triphasic profile where an initial burst is followed 
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by a steady slow release until polymer erosion onset leads to a second burst. A burst 
release can be caused by particle swelling, crack formation or the hydration of drug 
particles on the surface of the polymer matrix. This is substantially influenced by the 
solubility of the drug as can be depicted from Fig. 1 B. Hence, hydrophilic drugs which 
get hydrated much easier than hydrophobic ones get released initially in a more 
prominent and faster way [65]. Furthermore, the velocity of this process can be 
influenced by the molecular weight of PLGA as small chains increase diffusion. The 
slow release phases which can occur between burst releases are mainly driven by 
drug diffusion out of the polymer matrix. In this phase the velocity is highly dependent 
on the density and porosity of the polymer matrix. Also drug-polymer and drug-drug 
interactions can be decisive [61].  
 
A             B 
 
Fig. 1 A): Typical release profiles for different drug/polymer compositions in PLGA drug release kinetics. 
B) Typical burst release drug release profiles of hydrophilic and hydrophobic drugs out of PLGA carriers. 
(A.U. was used as an arbitrary unit used for drug release time) [63]. 
Crystallinity of PLGA is another factor which defines the degradation and drug release. 
Lower crystallinity generally improves faster drug release especially if diffusion is the 
main release type at hand. The composition of lactic acid (LA) to glycolic acid (GA) and 
the choice of LA isomer determine whether the copolymer turns out amorphous or 
semi-crystalline [66]. Hydrophobicity is another feature which can be easily adjusted 
by the ratio of LA to GA, because of the methyl group which is incorporated in the LA 
monomer [63]. 
To summarize, PLGA can be viewed as a chemical “construction kit” which can be 
formed for specified needs in drug delivery. All the various modification possibilities 
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like molecular weight or monomer block ratios can be chosen individually for each drug 
and application route. An overview with all the modification options for PLGA 
production is displayed in Scheme 5. This, and the fact that many medical products 
and carrier systems made of PLGA are approved by the FDA make the polymer to one 
of the most used carrier matrix agents nowadays [60, 61, 63, 64]. 
 
 
Scheme 5 - Summary of all the set screws which can be altered for individual polymer matrix production 
for each drug and application route [63].  
 
1.6 Aim of the thesis 
 
Successful expression of proteins derived from applied nucleic acids without activating 
the immune system is today as much a challenge as it has been in the first successful 
transfection trials in vivo made by Wolff et al. in 1990 [67]. Nowadays, the modification 
of nucleic acids complexing agents, has been extensively studied and improved to 
better reach this goal. To this day very few products based on this technology survive 
clinical trial testing because of their lack in functionality or limits-exceeding toxicity and 
immunogenicity [68, 69]. Especially the field of chemically modified mRNA delivery for 
protein production in vivo provides a rather new and promising approach of transcript 
therapy, with all its challenges in terms of complexation, specific cell targeting, cell 
uptake, endosomal escape and translation in the cytosol [70]. The task at hand for this 
thesis was not only to develop alternative complexing agents for the direct delivery of 
cmRNA but also to find strategies which enhance already established delivery systems 
by the help of tissue engineering techniques. The common basis for all the efforts here 
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has been the biocompatible polymer poly (lactic-co-glycolic acid). This work is divided 
in two main projects which contributed to this thesis.  
Aim of the first project was the development, analysis and optimization of an 
intermediate phase which allows the incorporation and release of cmRNA comprising 
lipoplexes into calcium phosphate cements (CPC). Injectable CPCs are self-hardening 
cements, which have been in clinical use for the last years and have the potential to 
replace polymethylmethacrylate (PMMA) bone fillings in applications like kyphoplasty 
or vertebroplasty [71-75]. Due to the similarity to the ceramic phase of endogenous 
bone, hydroxyapatite and calcium phosphate mixtures comprise a substantially better 
biocompatibility than PMMA, but the relatively long periods of biodegradation hinder 
fast cell-ingrowth and the replacement of such implants by endogenous bone. Hence, 
to imitate natural bone, fiber or microparticle-based calcium phosphate composites 
have been of interest to enhance mechanical elasticity and to decrease degradation 
times significantly. PLGA- based microparticles mixed to these injectable cements are 
just one possibility to enhance these products for a faster degradation in vivo [58, 76, 
77]. In this project, the possibility of encapsulating cmRNA bearing lipoplexes into such 
microparticles for a fast release of lipoplex after contact with physiological media was 
desired. First, the incorporation procedure of lipoplexes into such PLGA-based 
microparticles was developed and optimized for initial lipoplex release, leading to 
immediate transfection efficiency in vitro. After the development and investigation of 
the standard operating procedure for microparticle formation the microparticles were 
incorporated into calcium phosphate cements and tested in vitro for their transfection 
potential as part of a composite structure. 
The aim of the second project was to find a cmRNA complexation agent and delivery 
system for potential applications to tissue types where mucus is present. Deacetylated 
chitin or chitosan is well known for its advantageous properties in crossing mucus 
barriers and is able to complex other nucleic acids, like siRNA or DNA, because of 
primary amine groups on the polymer backbone [38, 41, 42, 78]. Hence, the idea was 
to establish and develop a chitosan-based cmRNA complex as a functional polyplex 
for cell transfection. Here, a thorough analysis of chitosan/cmRNA polyplexes in terms 
of physicochemical properties, biocompatibility and transfection efficiency in vitro was 
planned and performed. Due to lacking colloidal stability of chitosan-based 
nanoparticles, the next step in polyplex development and optimization for transfection 
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efficiency in vitro was a co-formulation process with PLGA. PLGA polymers in 
nanoparticles are known to increase polyplexes’ capacity to compact the cargo for the 
prevention of premature degradation in physiological conditions and furthermore 
enhance the colloidal stability of such systems [79, 80]. After the optimization of the 
co-formulation process a comparison of chitosan- and co-formulated PLGA/chitosan 
polyplexes was performed. Features like of physicochemistry, colloidal stability in 
physiological simulations, transfection efficiency and cytotoxicity on mouse fibroblasts 
were analyzed for their potential of being a potential candidate for future in vivo testing.  
Materials and methods 
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2 Materials and methods 
 
In the following chapter all chemicals, devices and methods, which were used for both 
projects, are listed and described.  
2.1 Materials 
2.1.1 Chemicals - microparticle project 
 
   Lipoplex formation: 
Ethanol, HPLC grade Carl Roth, Karlsruhe, Germany 
C12-(2-3-2) Ethris, Planegg, Germany 
1,2-dioleoyl-sn-glycero-3-phos-phoethanolamine  Avanti Polar Lipids, Alabastar, USA 
1-palmitoyl-2-[11-(dipyrrometheneboron difluoride)- 
undecanoyl]-sn-glycero-3-phosphoethanolamine Avanti Polar Lipids, Alabastar, USA 
Plant derived cholesterol Avanti Polar Lipids, Alabastar, USA 
1,2-Dimyristoyl-sn-glycerol, methoxypolyethylene Glycol  NOF America, White Plains, USA 
Water for injection B.Braun, Melsungen, Germany 
Citric acid ≥ 99,5 % Carl Roth, Karlsruhe, Germany 
Sodium chloride ≥ 99,5 % Carl Roth, Karlsruhe, Germany 
Sodium hydroxide solution 5N Carl Roth, Karlsruhe, Germany 
   Microparticle formation: 
Resomer® RG 750 S Evonik, Darmstadt, Germany 
Resomer® RG 752 S Evonik, Darmstadt, Germany  
Resomer® RG 755 S Evonik, Darmstadt, Germany 
Resomer® RG 858 S Evonik, Darmstadt, Germany 
Resomer® RG 502 H Evonik, Darmstadt, Germany 
Resomer® RG 503 H Evonik, Darmstadt, Germany 
Resomer® RG 504 H Evonik, Darmstadt, Germany 
Dichloromethane, for peptide synthesis Carl Roth, Karlsruhe, Germany 
Poly (vinyl alcohol) 31.500-50.000 Mw Sigma Aldrich, St. Louis, USA 
Phosphate saline buffer (1x)  Gibco, Eggenstein, Germany 
   Microparticle Analysis: 
Heparin sodium salt from porcine mucosa Sigma Aldrich, St. Louis, USA 
Dimethylsulfoxide, BioScience grade Carl Roth, Karlsruhe, Germany 
Coelenterazine, native ≥ 95 % Synchem, Grove Village, USA 
Methanol, HPLC grade Carl Roth, Karlsruhe, Germany 
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   Ceramic/polymer composition: 
Calcibon® paste BioMet, Munich, Germany 
   Cell Culture: 
Dulbecco’s modified eagle medium GlutaMax, Low Glucose Gibco, Eggenstein, Germany 
Trypsin-EDTA (0,05%), phenol red Gibco, Eggenstein, Germany 
Accutase Cell Detachment Solution Gibco, Eggenstein, Germany 
Phosphate saline buffer (1x)  Gibco, Eggenstein, Germany 
Penicillin-Streptomycin (10000 U/ml) Gibco, Eggenstein, Germany 
Fetal Bovine Serum, qualified, E.U.-approved Gibco, Eggenstein, Germany 
   cmRNA (encoding proteins): 
Metridia Luciferase Ethris, Planegg, Germany 
Firefly Luciferase Ethris, Planegg, Germany 
Erythropoietin Ethris, Planegg, Germany 
Green Fluorescent protein Ethris, Planegg, Germany 
Td Tomato Ethris, Planegg, Germany 
   Dyes: 
Label IT® TM-Rhodamine Labeling Kit  (Mirus Bio, Madison, USA)  
   Water: 
Water for injection B.Braun, Melsungen, Germany 
Aqua bidest. Kerndl, Weissenfeld, Germany 
2.1.2 Chemicals - nanoparticle project 
 
   Polymers for particle formation: 
Protasan UP CL 113, Mw <150 kDa FMC BioPolymer AS, Oslo, Norway 
Polyetheylenimine, branched 25.000 Mw Sigma Aldrich, St. Louis, USA  
   Poly (lactic-co-glycolic acid) (PLGA): 
Resomer® RG 750 S Evonik, Darmstadt, Germany 
Resomer® RG 502 H Evonik, Darmstadt, Germany  
Resomer® RG 858 S Evonik, Darmstadt, Germany 
   Surfactants: 
Poly (vinyl alcohol) 31.500-50.000 Mw Sigma Aldrich, St. Louis, USA 
Poly (vinyl alcohol) 9.000-10.000 Mw Sigma Aldrich, St. Louis, USA 
   Organic solvents: 
Dichloromethane, for peptide synthesis Carl Roth, Karlsruhe, Germany 
Ethyl acetate Sigma Aldrich, St. Louis, USA 
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   Gel electrophoresis: 
Agarose Standard Carl Roth, Karlsruhe, Germany 
TRIS-acetate-ethylenediaminetetraacetic acid (EDTA) Carl Roth, Karlsruhe, Germany 
peqGREEN®, RNA/DNA dye  VWR, Pennsylvania, USA 
   Cell Culture: 
Dulbecco’s modified eagle medium GlutaMax, Low Glucose Gibco, Eggenstein, Germany 
Trypsin-EDTA (0,05%), phenol red Gibco, Eggenstein, Germany 
Phosphate saline buffer (1x)  Gibco, Eggenstein, Germany 
Penicillin-Streptomycin (10000 U/ml) Gibco, Eggenstein, Germany 
Fetal Bovine Serum, qualified, E.U.-approved Gibco, Eggenstein, Germany 
   Cytotoxicity assay 
3-(4,5-Diemethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (MTT) Trevigen, Gaithersburg, Germany 
α-D(+)-Glucose Monohydrat Carl Roth, Karlsruhe, Germany 
Triton® X-100 Carl Roth, Karlsruhe, Germany 
2-Propanol, HPLC grade Carl Roth, Karlsruhe, Germany 
Hydrochloric acid, 1N Carl Roth, Karlsruhe, Germany 
Phosphate saline buffer (1x)  Gibco, Eggenstein, Germany 
   cmRNA (encoding proteins): 
Metridia Luciferase Ethris, Planegg, Germany 
Firefly Luciferase Ethris, Planegg, Germany 
Green Fluorescent protein Ethris, Planegg, Germany 
   Dyes: 
RNA Gel Loading Dye Thermo Fisher, Waltham, USA 
DBCO-Sulfo Cyanin 3 Jena Biosciences, Jena, Germany 
DBCO-Sulfo Cyanin 5 Jena Biosciences, Jena, Germany 
   In Vivo test: 
D-Luciferin sodium salt Synchem, Grove Village, USA 
   Water: 
Water for injection B.Braun, Melsungen, Germany 
Aqua bidest. Kerndl, Weissenfeld, Germany 
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2.2 Methods – general protocols 
 
Some of the analysis methods conducted in this thesis were both used in the 
nanoparticle and microparticle projects. Those general methods are described in the 
next chapter. 
 
2.2.1 Measurement of nanoparticle size 
 
Nanoparticle dispersions were measured by dynamic light scattering method (DLS) via 
a Zetasizer Nano ZS (Malvern, Worcestershire, United Kingdom). Here, a cumulant 
mean or Z-average size is defined as the harmonic intensity averaged particle diameter 
and certified under ISO 13321/ ISO 22412. This parameter is a hydrodynamic value 
and therefore only applicable to particles in dispersion or solution. Cumulants analysis 
results in a mean size value and a polydispersity index which is dimensionless and 
provides information about the homogeneity in size of the particles in dispersion [81]. 
For every measurement the refractive index was adjusted to each solvent, the particles 
were synthesized in. 100 µl of dispersion was measured in a disposable cuvette in 
triplicates with at least 10 measurements, each. For each measurement particle 
dispersion concentrations of at least 10 µg cmRNA/ml were used. 
 
2.2.2 Measurement of nanoparticle zeta potential 
 
Particles were analyzed for their surface charge via Zetasizer Nano ZS (2.2.1), as well. 
The Zeta potential in mV is defined as the potential at the boundary of particles 
dispersed in a fluid and gives insight into colloidal stability via ionic repulsion. The 
higher a particle is charged the faster those particles will repulse themselves from each 
other which can be measured via light scattering of a set laser beam. The 
electrophoretic mobility when a certain electric field is applied to the dispersion is 
proportional to certain frequencies, detected by light scattering and can therefore be 
recalculated to a surface charge or Zeta potential [82]. For every measurement 750 µl 
of particle dispersion were added to a special reusable cuvette where electrodes were 
attached on the sides to apply the electric current for measurement. Every sample was 
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conducted in triplicates with at least 10 measurements, each. As for size 
measurements particle dispersion concentrations of at least 10 µg cmRNA/ml were 
used. 
 
2.2.3 Cell culture 
 
In the two projects depicted here, three different cell lines for in vitro assays of various 
kinds were used. The pre-screening for microparticle synthesis analysis was 
completely done with rat derived bone marrow stem cells (rBMSCs), the general bio-
functionality and cytotoxicity tests for both nano- and microparticles were conducted 
on mouse fibroblasts (NIH3T3) and the composite calcium phosphate/PLGA bio-
functionality tests were done on (C2C12) mouse myoblasts with the potential for 
differentiation to osteoblasts [83]. All of those cell lines were cultivated with the same 
media and conditions:  
After thawing frozen cell (in DMSO) vials from an in-house cell bank, cells were 
cultivated in Dulbeccos’s modified eagle medium (DMEM) containing 10 % fetal bovine 
serum (FBS) and 1 % Penicillin/Streptomycin (Pen/Strep). After confluency was 
reached the cells were washed with PBS and subsequently trypsinated (accutase 
treatment for rBMSCs) and passaged up to 20 times for in vitro assays. Cell counting 
was done by an automated cell counter (Countess II, Thermo Fisher Scientific, 
Waltham, USA) and seeding into standardized 96, 48 and 24 well plates (Corning, New 
York, USA). 
 
2.2.4 Scanning electron microscopy 
 
For the visualization of nanoparticle- and microparticle surfaces and their subsequent 
analysis a Scanning electron microscope (SEM) (Zeiss-Leo DSM 982 Gemini, FELMI-
ZFE, Graz, Austria) was utilized. Images were taken at a chamber current of 5 kV. 
Sputtering was done with a mixture of 60/40 gold/palladium by a sputter coater 
(Edwards S150B, HHV Ltd, West Sussex, UK) for 1 min at 40 W and 7.5 mbar. 
Nanoparticles were analyzed without sputtering at the same conditions. 
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2.3 Methods - microparticle project 
2.3.1 Lipoplex formation 
 
Nano-sized lipoplexes were prepared by a simplified method as described in 
Jarzebinska et al. [47]. In brief, an ethanol phase containing the oligoalkylamine N,N’-
Bis(2-aminoethyl)-1,3-propanediamine modified with C12 alkylchains (C12-(2-3-2), 
(1,2-dioleoyl-sn-glycero-3-phos-phoethanolamine (DOPE), plant derived cholesterol 
and 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (DMG-PEG-2k) at molar 
ratios of 8/5.29/4.41/0.88, was complexed with cmRNA (dissolved in a 10 mM citrate/ 
150mM sodium chloride buffer solution; pH 4.5) by a solvent exchange method in a 
volume to volume ratio of 0.2 ethanol to aqueous phase. Both phases were equilibrated 
for 10 min, before the ethanol phase was injected into the water phase using an insulin 
syringe with subsequent vortexing for 15 s. The subsequent nanoparticle dispersion 
was equilibrated for 30 min at room temperature before it was ready to use. The final 
concentration of cmRNA was 0.2 mg/ml at an N/P (nitrogen to phosphate) ratio of 17. 
Lipoplex dispersion were stored at 4 °C and could be used for at least four weeks 
without significant loss of functionality. 
 
 
2.3.2 Fluorescence labelling for fluorescence microscopy 
 
cmRNA was labelled by two different routes in this study. First of all, cmRNA coding 
for erythropoietin (EPO) was labelled with a TM-Rhodamine dye for detection by 
fluorescence microscopy. The dye consists of a fluorophore connected to a linker unit 
which is responsible for electrostatic interaction with the nucleic acids and a reactive 
alkylating group which covalently attaches to heteroatoms in the RNA strands [84]. 
Labelling was conducted with a ready-to-use label-IT® TM-Rhodamine dye (Mirus Bio, 
Madison, USA) as recommended by the manufacturer. 50 µg of EPO cmRNA were 
treated and a theoretical coupling of 7.85 labels per nucleic acid was calculated. 
cmRNA was detected via a fluorescence microscope (Leica DMi8) with an external 
laser source for excitation (Leica EL 6000). TM-Rhodamine has its excitation maximum 
at 546 nm and emits best at 576nm. 
Materials and methods 
24 
 
 
2.3.3 Microparticle formation 
 
PLGA microparticles were synthesized by an adjusted water/oil/water solution double 
emulsion solvent evaporation technique [85-87]. An outline of the procedure can be 
seen in Scheme 6. An organic phase was prepared by dissolving PLGA in 2 ml 
dichloromethane (DCM). The first aqueous solution consisted of freshly prepared 
lipoplex dispersion (0.2 mg cmRNA/ml), diluted with PBS to a total volume of 2 ml. The 
aqueous phase in particle formations where no lipoplexes were encapsulated 
consisted of 2 ml PBS. The lipoplex dispersion was dispensed dropwise into the 
organic phase and the mixture was sonicated by an ultrasonic probe (Branson Digital 
Sonifier 250-D, Dansbury, USA) for varying pulse lengths and at different sonication 
intensities. The resulting emulsion was subsequently given dropwise into a second 
aqueous solution consisting of 6 ml 4 % poly (vinyl alcohol) (PVA) (30-55kD) in water. 
This emulsion was vigorously vortexed for at least 10 s and added dropwise to a 
second PVA solution in water (8 ml; 1 % PVA) while mixing on a magnetic stirrer. After 
the organic solvent evaporated completely (emulsion turned from milky to slightly 
transparent), the resulting microparticle dispersion was centrifuged at 3000 x g and 
washed three times with water. After resuspension with 5 ml of water the particles were 
snap-frozen in liquid nitrogen and lyophilized (Christ Alpha 2-4; Osterode am Harz, 
Germany) overnight. The dry powder was weighed to determine the yield and stored 
at -20 °C. 
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Scheme 6 - Schematic representation of the PLGA microparticle preparation process. A water-in-oil-in water 
emulsion solvent evaporation technique was used for the synthesis of encapsulating lipoplexes in the 
polymer matrix 
 
 
2.3.4 Measurement of microparticle size 
 
For the measurement of mean diameter and standard deviation of the PLGA 
microparticles, powders were suspended in water and investigated under the light 
microscope (Carl Zeiss, Axiovert 25, Jena, Germany) on a standard glass microscope 
slide. Three images at different fractions of the slide were captured at a magnification 
of 10 by a microscope camera (Carl Zeiss, AxioCam ERc 5s, Jena, Germany) (Fig. 2). 
A macroinstruction programmed for ImageJ was used to convert the image to a binary 
state (Fig. 3). Particles were subsequently counted and measured for particle areas, 
ferrets and amounts of particles (Fig. 4). From this data set the mean diameter, and its 
deviation for one microparticle batch was determined in triplicates. A copy of the 
macroinstruction can be found in the appendix (7.3) 
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Fig. 2 –  Exemplary image of PLGA microparticles taken by light microscopy at a magnification of 10 
 
Fig. 3 -  Binary image of Fig. 2 after image post processing by ImageJ. Microparticles are indicated in 
black color 
 
Fig. 4 - post processed image of Fig. 3. Particle analysis via particle detection with programmed criteria. 
Only particles with a round shape and certain size were detected and analyzed 
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2.3.5 cmRNA quantification protocol in microparticles 
 
To determine how much cmRNA was encapsulated in how much microparticle polymer 
the PLGA matrix had to be dissolved first without destroying the cargo. Microparticle 
dissolving was achieved by dimethyl sulfoxide (DMSO) addition and shaking. 
Depending on size and porosity of the microparticles the time for dissolving deviated 
from a few seconds to 2 h while shaking on a Thermomixer (Eppendorf ThermoMixer® 
5436, Hamburg, Germany) at room temperature. cmRNA displacement from the 
lipoplexes dissolved in DMSO was done by the addition of heparin sodium salt from 
porcine mucosa. As the salt is not soluble in DMSO, it was dissolved in water prior to 
mixing with DMSO in a concentration of 10 mg/ml. Water to DMSO ratio was 3/7. 
cmRNA displacement via heparin interaction with the cationic lipids was done at 70°C 
and shaking at 7000 rpm on a Thermomixer. Encapsulation efficiency of cmRNA in 
microparticles could be subsequently measured by Quant-iT RiboGreen® Assay. 
Nucleic acids react with the dye which leads to a shift in its emission behavior. This 
was quantitatively detected by a multilabel plate reader (Wallac Victor, Perkin-Elmer 
Life Sciences, Waltham, USA) at an excitation/emission maximum of 500/525 nm. 
 
2.3.6 Surface topology investigation 
 
Particle powders were attached on a graphene sheet and coated with gold and 
palladium at a ratio of 60/40 with a sputter coater (Edwards sputter coater S150B, HHV 
Ltd., West Sussex, UK) for 1 min at 40 W and 7.5 mbar. The sputtered particles were 
subsequently scanned by a Zeiss-Leo DSM982 Gemini (FELMI-ZFE, Graz, Austria) 
scanning electron microscope at 5 kV and investigated by ImageJ (Fig. 5).  
A macroinstruction (appendix 7.3) programmed for ImageJ was used to analyze the 
porous areas divided by the total surface area on the microparticles. Here, well defined 
particle surface areas with low differences in brightness were chosen manually for 
further examination. Those areas were defined as indicated in Fig. 6.  These areas 
were converted into a binary state, in which the black pore areas could be quantified 
and divided by the total area which is visible on the raw data images. This form of 
measurement is an artificial quantification of surface pore areas which does not reflect 
any 3-dimensional porosity volume values. A quotient of black to grey areas from the 
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raw data images (Fig. 5) was calculated as a dimensionless measure of porosity  
(Fig. 7). Three images of each batch of microparticles were investigated to obtain a 
mean value and standard deviation of detected pore areas divided by total surface 
areas. 
 
Fig. 5 - Exemplary images of PLGA microparticles taken by scanning electron microscopy at a 
magnification of 1000. 
 
Fig.  6 - selected areas of Fig. 5 where smooth surface area is distinguishable with pore areas.         
 
Fig. 7 - pore area quantification in the areas detected in Fig. 5 
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2.3.7 In vitro transfection efficiency  
 
The expression of the cmRNA encoded protein (metridia luciferase) after transfection 
of murine fibroblasts/myoblasts was used to determine lipoplex efficiency and 
functionality after release from the microparticle matrix [88]. Cells were cultivated in 
Dulbecco’s modified eagle medium (DMEM-GlutaMax Low Glucose) containing 10 % 
fetal bovine serum (FBS), 1 % Penicillin/Streptomicin (Pen/Strep) and were freshly 
trypsinated before seeding onto 24/48-well plates at a density of 50000/30000 
cells/well with 500/250 µl, respectively. Microparticles were subsequently added to the 
cell/medium mix at various dosages of cmRNA on a defined number of cells before cell 
adhesion. In CPC/PLGA composite trials a dosage of 20 pg cmRNA/cell was used. 
After the addition of coelenterazine buffer, containing a 50 mM PBS-buffer (pH 7.0) to 
100 µl of the supernatants, collected 24, 48, 72 and 96 h after transfection, 
luminescence was measured in triplicates using a luminescence reader (Wallac Victor, 
Perkin-Elmer Life Sciences, Waltham, USA). Most of the microparticles adhered to the 
cell monolayer after 24 h which enabled simple medium exchange after supernatant 
investigation. Hence, the protein production between each time point of measurement 
was investigated independently.  
 
2.3.8 Composite mixing with bone substitute materials 
 
Polymer/cement composites were prepared by direct mixing of powders in weight-to-
weight (w/w) ratios from 100:0, 90:10, 80:20 to 70:30 Calcibon® (BioMet, Munich, 
Germany) to PLGA microparticles after freeze drying. The powders were mixed via a 
dental shaker for 30 s to obtain a homogeneous product. Curing was initiated by 
disodium hydrogen phosphate (Na2HPO4, 2.5 mg/ml) which was delivered with the 
Calcibon® powder as a ready-to-use kit. All the specimens were cured with a powder 
to liquid ratio of 2.5 % (w/v) and the mixture was prepared as recommended by the 
distributor. For transfection, powder mixes were prepared directly in a 48-well plate 
and shaped by a spatula where approximately half of the well bottom was covered with 
the hardened composite and the other half kept free for cell attachment. For the µ-CT 
investigation the powders were cured and formed to cylindrical shapes. 
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2.3.9 µ-CT analysis of composites 
 
Composite specimens were analyzed by a non-invasive 3D CT examination (CT µ40; 
Scanco Medical AG, Bassersdorf, Switzerland). The increment was set to 157 µm with 
an angle of 0°. Scanning was done at an isotropic voxel size of 10 µm (55kVp, 145 
mA; lCT 40). The voxel size of the images was set to 8000 µm with a total number of 
500 slices. The integration time of the beam was set to a maximum of 300 ms and two 
data sets for each slice were recorded. The raw data was processed by ImageJ/BoneJ 
[89]. Each specimen was examined as a whole and a fraction in the sample was 
chosen randomly for density comparisons by ImageJ. Virtual discs of a diameter of 2 
mm and 99 slices were analyzed (Fig. 8 A). The greyscale threshold to distinguish 
between dense and high-crystalline cement phases and low-crystalline/density phases 
were determined individually for each specimen. In Fig. 47 (supplementary 
information) a schematic description of the analysis is depicted. A triplicate of 
greyscale measurements at areas outside of the composites in a µ-CT slide was done 
to determine the threshold for the high-density cement phase. The maximum level of 
the greyscale (100 % white) inside the composites was defined as the upper limit of 
the high-density cement phase. Volume to volume ratios of CPC/PLGA composites 
were calculated and illustrated via a greyscale threshold method. Due to substantial 
density differences between polymer and cement phase, the threshold could be set 
manually. The cement phase could be qualitatively identified as red pixels (Fig. 8 B). 
A                   B 
  
Fig. 8 – A) Exemplary image of a volume disc virtually cut out of a composite specimen, the blue box 
indicates the defined volume which was analyzed and the yellow masses represent the ceramic fraction of 
the disc. B) Exemplary slice of a volume disc displaying random parts of a CPC/PLGA specimen. The 
cement phase is marked in red color.  
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2.4 Methods – nanoparticle project 
 
2.4.1 Preparation of chitosan and co-formulated PLGA/chitosan polyplexes 
 
In Scheme 7 the formation of nanoparticles with and without PLGA is displayed. 
Chitosan/cmRNA complexes were formed by one-pot mixing of different amounts of 
chitosan (Protasan UP CL 113), and cmRNA at different concentrations and constant 
volume to volume ratios of 1/1 for each N/P ratio. As described below, nitrogen from 
primary amines on chitosan, and phosphates, from cmRNA backbones define N/P 
ratios which were used as a guideline to investigate the interaction of the cargo and its 
encapsulating agent. Here, the amount of substance (mol) of the chitosan’s 
deacetylated fraction which carries one free primary amine on each monomer was 
divided by the amount of substance (mol) of the phosphates in a typical cmRNA. A 
mean molecular weight of 340 g/mol was defined per cmRNA base. For N/P 1, 2, 4, 8, 
10, 15, 20 a volume of 60, 120, 240, 480, 560, 900, and 1200 µl of chitosan solution 
(2.5 mg/ml) was mixed to 300 µl of cmRNA (1 mg/ml) solution, respectively. The 
resulting dispersion was vigorously vortexed for 30 s. After equilibration for 10 min at 
room temperature chitosan polyplexes were ready to use. For the co-formulation with 
PLGA (Resomer® RG 750 S), 200 µl of dissolved poly (vinyl alcohol) (PVA, 10%) were 
added to 2 ml of the chitosan nanoparticle dispersion after equilibration and was diluted 
with water to 4 ml. The subsequent aqueous phase was mixed with 20 mg of poly 
(lactic-co-glycolic acid) (PLGA) dissolved in 6 ml dichloromethane (DCM) via a 
microfluidic syringe pump. The resulting emulsion was stirred for 4 h. Two 
centrifugation steps at 15000x g for 5 min and 110000x g for 1 h, were utilized for 
agglomeration filtering and nanoparticle washing [90].  
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Scheme 7 - Schematic representation of the Chitosan/PLGA/cmRNA-complex preparation process. Self-
assembling of chitosan/cmRNA particles takes place before co-formulation with PLGA by a water-in-oil 
emulsion solvent evaporation technique was conducted. 
 
 
2.4.2 Fluorescence labelling for FRET analysis 
 
For FRET analysis a chemically modified firefly luciferase-encoding cmRNA where all 
uridines bear an azide was utilized for coupling via copper-less click-chemistry. Both 
Cyanin-3 (Cy3) and Cyanin-5 (Cy5) fluorophores are attached to a DBCO group with 
a labile triple bond. DBCO and the azides covalently bond in a one pot reaction at 4°C 
for 2 h. A coupling of 10 % of free azide for both dyes was conducted in each 50 µg of 
cmRNA by using 2,455 nmol of dye (quantity of substance was calculated via the ratio 
of azide bearing bases and the molecular weight of cmRNA). The excitation maximum 
of Cy3/Cy5 is at 553/646 nm and emits best at 563/661 nm. FRET signal was quantified 
by a Tecan microplate reader Infinite® 200 PRO (Tecan, Männedorf, Switzerland). 
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2.4.3 cmRNA quantification in polyplexes 
 
To determine the encapsulation efficiency and the yield after co-formulation with 
PLGA, the cmRNA concentration in a freshly formed PLGA/chitosan polyplex 
dispersion was conducted via Quant-iT RiboGreen® assay. 200 µl of polyplex 
dispersion was used for displacement by 50 µl of heparin (40 mg/ml) interaction 
including 50 µl of Triton X-100 (2%) at 70°C and shaking at 7000 rpm on a 
Thermomixer. Encapsulation efficiency of cmRNA in co-formulated particles could be 
measured subsequently by the addition of 100 µl Quant-iT RiboGreen® working 
solution to 100 µl of the specimen described above. For cmRNA quantification after 
copolymerization unbound cmRNA was used for defining calibration curves. The 
fluorescence shift of the dye to higher wavelengths after reaction with cmRNA was 
quantitatively detected by a multilabel plate reader (Wallac Victor, Perkin-Elmer Life 
Sciences, Waltham, USA) at an excitation/emission maximum of 500/525 nm. 
 
 
2.4.4 Agarose gel electrophoresis 
 
For gel formation, 150 ml of TRIS-acetate-ethylenediaminetetraacetic acid (TAE) 
buffer containing 1 % (w/v) agarose and 5 % peqGREEN®, RNA/DNA dye was used. 
The mixture was heated shortly in a microwave oven until agarose was completely 
dissolved. The fluid was poured into a gel template and hardened for approximately 
0.5 h. Before the samples were added, the gel was given into an electrophoresis 
template containing TAE buffer to cover the gel completely with fluid. The samples 
were treated with a loading dye 20 µl were subsequently added into the pockets of the 
gel. For cmRNA displacement in samples where cmRNA had to be freed from their 
carrier,10 µl of cmRNA complex dispersion was mixed with 2 µl of heparin (100 mg/ml) 
solution and 3 µl Triton® X-100 (2 %). As a next step the mix was equilibrated at 70 °C 
for 30 min, and subsequently added to 10µl of loading dye. Gel electrophoresis was 
performed at 150 V for 0.5 h. Analysis of the gels was executed by ChemiDoc XRS+ 
system and the images were post processed by ImageJ.  
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2.4.5 Fluorescence resonance energy transfer (FRET) 
 
For FRET studies nanoparticles were prepared (as described in 2.4.1 and 2.4.2) with 
10% of labelled cmRNA (80/20 % of Cy3/Cy5) and 90 % of green fluorescent protein 
(eGFP) encoding cmRNA. Here, cmRNA encoding for firefly luciferase, where all 
uridines were linked with an azide group, was labelled with DBCO-sulfo-Cyanin 3/5 
(Cy3/Cy5) and mixed to unlabeled cmRNA encoding for green fluorescent protein 
(eGFP) in a ratio of 1/9. Labelling was executed according to the instructions of the 
manufacturer with slight modifications to allow a loading of 10 % of the azide bearing 
uridines. The excitation maximum of Cy3/Cy5 is at 553/571 nm and emits best at 
646/662 nm, respectively. The FRET signal could be calculated as follows: 
 
FRET [ ] = Cy5 (679 nm) intensity/ Cy3 (517 nm) intensity [91-93]. 
 
The emission levels of both dyes were measured simultaneously by a Tecan® Infinite 
Pro 200 (Tecan, Männedorf, Switzerland) multimode reader 8, 15, 20, 30, 60, 90 and 
120 min after mixing the nanoparticle dispersions with different ratios to water, PBS, 
DMEM, FBS and 10 % of dissolved mucin.  
2.4.6 In vitro transfection efficiency  
 
NIH3T3 cells were cultivated in DMEM containing 10 % FBS and 1 % 
Penicillin/Streptomycin (Pen/Strep). 24 h before transfection, cells were trypsinated 
before seeding onto standard 96-well plates at a density of 10.000 cells/well. After cell 
attachment over night the cell culture medium was removed and different amounts of 
PBS or DMEM were mixed with the nanoparticle dispersions which were analyzed and 
added to the cell monolayer for different amounts of incubation time. The nanoparticle 
dispersions were exchanged with cell culture medium and the samples were incubated 
at 37 °C and 5 % CO2 for another 24 h. After the addition of coelenterazine buffer, 
containing a 50 mM PBS-buffer (pH 7.0) to 100 µl of the supernatants, collected 24 
and 48 h after transfection, bioluminescence was measured in triplicates using a 
luminescence reader (Wallac Victor, Perkin-Elmer Life Sciences, Waltham, USA). 
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2.4.7 In vitro cell viability assay (MTT) 
 
Cell viability was investigated by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-
bromide (MTT) assay. Here, by a colorimetric method based on the cleavage of yellow 
tetrazolium to insoluble crystalline formazan, the mitochondrial activity of living cells 
could be quantified [94]. Transfection prior to MTT testing was conducted as described 
in chapter 2.4.6. 24 h after transfection cell culture medium was replaced by 100 µl of 
MTT buffer consisting of 1 mg/ml MTT reagent and 5 mg/ml D-(+)-glucose dissolved 
in PBS. After 2 h of incubation at 37 °C and 5 % CO2 solubilisation of the crystals was 
achieved by the addition of 100 µl of 10 % Triton® X-100 in anhydrous isopropanol and 
0.1 N hydrochloric acid (HCl). Dissolved formazan was detected and quantitatively 
measured via a multiplate reader at a wavelength of 590 nm. As a reference, 8 wells 
were treated with water instead of nanoparticle dispersions while transfection on each 
plate. 
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3 Results 
 
The central subject of this thesis is the investigation of how PLGA as a biodegradable 
polymer can be utilized in different cmRNA delivery applications. One of those 
possibilities was the development of an intermediate cmRNA carrier for the 
enhancement of bone substitute materials. Initial experiments showed that ceramics 
like calcium phosphates, which are commonly used in bone defect filling, could not be 
utilized as functional scaffolds for cmRNA delivery on its own. Therefore, the idea 
emerged to include a bioactive composite, basically consisting of PLGA. The strategy 
to enhance the ceramic pastes by insertion of PLGA-based microspheres was already 
tested by other researchers in the field of calcium phosphate based bone substitutes, 
especially for introducing a fast-degrading composite to increase cell ingrowth and 
implant degradation [58, 76, 77]. However, the microparticles, desired in this project, 
were not only supposed to increase the porosity of such ceramics, but to release 
functioning cmRNA vehicles which are able to enhance bone growth by triggering i.e. 
growth factors like BMP-2.  
 
 
3.1 Optimization of the microparticle formation process 
 
PLGA-based microparticle formation for various applications has been described 
extensively over the last decades [85, 86, 95-99]. By simple reproduction of some of 
those described encapsulation routes, rather big (Fig. 9 A) or damaged spheres  
(Fig. 9 B) resulted as products after first formation trials. As the lipid nanoparticles have 
never been described as the cargo for encapsulation via an emulsion solvent 
evaporation technique with PLGA, optimization of these formulation routes was 
necessary. For this purpose, a scheme (Scheme 8) with all the critical steps was 
defined and each stage of the formation process was screened for its effect on the 
product.  
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A            B 
      
Fig. 9 – A) PLGA microparticles with a diameter of 150-500 µm; B) shredded PLGA microparticles. Spherical 
shape could not be achieved without optimizing the formulation process for lipoplex encapsulation. 
 
 
Scheme 8 -Schematic representation of the PLGA microparticle preparation process with the main factors 
for formation investigation in bold and the (intermediate) products in italic. For the investigation of 
parameter change impact factors, only one of the parameters was changed at a time, for each analysis. 
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Here, first and foremost, the reproducibility in shape and size, and the transfection 
efficiency of the microparticle powders were defined as key properties. In a pre-
screening, the organic phase, the aqueous phase, the surfactants and the energy 
intake for interphase mixing were investigated for their impact on the properties 
mentioned above. For all the following results three independently produced batches 
were formulated for each experimental setting to collect independent triplicates for 
analysis. 
 
3.1.1 Influence of the organic phase: PLGA (Resomer®) 
 
Seven different types of PLGA (Resomer®) with three different grades of 
hydrophobicity and varying chain lengths have been investigated to define the optimal 
carrier properties for the purpose of lipoplex encapsulation. Resomer® was chosen 
because these polymers have already been tested and used in various approved 
medical products [100]. A full list of all the different PLGA types is displayed in  
Table 1. 
 
Table 1 - Overview of the different Resomer® types which were used in this study. Properties like the ratio 
between glycolic acid and lactic acid monomers, the endgroup, degradation timeframe after implantation 
and the inherent viscosity (directly proportional to molecular weight) are depicted for each [100]. 
 
The polymers can be grouped into two different families of polymers. 502 H, 503 H and 
504 H are polymers where the ratio between glycolic acid and lactic acid monomers is 
1:1. The H indicates carboxyl groups on the polymers’ ends. 750 S, 752 S, 755 S and 
858 S are PLGA polymers with an ester termination and a monomer ratio of 3:1 and 
6:1, respectively, in favor of lactic acid. As shown in scheme 4 (chapter 1.5) the only 
difference of the monomers is an additional methylene group on the lactic acid 
monomer. Due to this small difference, chemical, physical and mechanical properties, 
including crystallinity, differ substantially between all the different types of PLGA used 
in this study. In Fig. 10 the effect of Resomer® type on microparticle formation is 
Resomer®	name 502	H 503	H 504	H 750S 752	S 755	S 858	S
Glycolic-/	Lactic	Acid	(GA/LA) 1:1 1:1 1:1 1:3 1:3 1:3 1:6
Endgroup Acid Acid Acid Ester Ester Ester Ester
Degradation	timeframe <	3	months <	3	months <	3	months <6	months <6	months <6	months 	9	months
Inherent	viscosity	[dl/g] 0.16	-	0.24 0.32	-	0.44	 0.45	-	0.60 0.8	-	1.2 0.14	-	0.22 0.5	-	0.7 1.3	-	1.7
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depicted concerning size and transfection efficiency of the microparticles after 
lyophilization. 
 
 
A             B 
 
Fig. 10 – A) Particle size measurement of microparticles formed with different PLGA/Resomer® types  
B) Transfection efficiency of microparticles formed with different PLGA/Resomer® types on mesenchymal 
rat bone marrow stem cells (rBMSCs). The reporter protein (metridia luciferase) activity was determined 
after 24 h post transfection by measuring bioluminescence expressed in counts per second (cps) 
 
The results for particle size measurements and transfection efficiency revealed biggest 
differences between polymers containing a lactic acid to glycolic acid (LA/GA) ratio of 
1:1 and polymers containing more lactic acid than glycolic acid. In general, particles 
made of Resomer® 502 H, 503 H and 504 H were approximately double in mean size 
than the particles made of the other tested polymers. Furthermore, a decline in mean 
size with increasing inherent viscosity for could be observed (Table 1). The same trend 
in size analysis was observed with the microparticles which were made of ester-
terminated PLGA types from 750 S to 858 S. Concerning transfection efficiency in vitro 
the trends within polymers with higher and lower lactic acid content were similar to the 
size measurements. From 502 H to 504 H, and therefore from low to high inherent 
viscosity, protein production decreased substantially. Bioluminescence was 
approximately one magnitude lower for all particles made of low LA content polymers 
than the particles made of polymers from 750 S to 858 S. Here 750 S was the best 
performing carrier polymer. Due to these results Resomer® 750 S was chosen for 
further optimization. In Fig. 11 and 12, exemplary images of microparticles reveal the 
main differences in particle topology, which were observed between particles made of 
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lower (GA:LA = 1:1) (Fig. 9) and higher (GA:LA £ 1:3) (Fig. 10) lactic acid monomer 
containing polymers and between acid- and ester terminated PLGA types, 
respectively. 
 
 
A           B 
   
Fig. 11 – A) Exemplary image of hydrophilic Resomer® 503 H and B) Resomer® 504 H-based microparticles 
taken by scanning electron microscopy at a magnification of 2000 
A           B 
    
Fig. 12 – A) Exemplary image of hydrophobic Resomer® 858 S and B) Resomer® 752 S-based microparticles 
taken by scanning electron microscopy at magnifications of 1000 and 2000, respectively 
Representative for the polymers with lower lactic acid content and acid-termination, 
particles in Fig. 9 present sponge-like, highly porous spherical structures under the 
electron microscope. In contrast, particles made of PLGA types with higher lactic acid 
content and ester-termination (Fig. 10) exhibit a smoother surface with defined and 
smaller surface pores.  
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3.1.2 Influence of the surfactant: poly (vinyl alcohol) (PVA) solutions 
 
The stabilization of the emulsion, in which the evaporation of the organic solvent takes 
place, is crucial for the spherical shaping and hardening in the microparticles’ formation 
process. The effect of surfactant concentrations was investigated and results are 
shown in Fig. 13 for the first- and Fig. 14 for the second aqueous solution. Below the 
PVA concentration levels shown, the emulsion collapsed and no particles could be 
obtained. 
 
 
A           B 
 
Fig. 13 – A) Particle size measurement of microparticles formed with different PVA concentrations in the 
first aqueous solution of the particle formation process. B) Transfection efficiency on rat bone marrow stem 
cells of microparticles formed with different PVA concentrations in the first aqueous solution of the particle 
formation process. The reporter protein (metridia luciferase) activity was determined after 24 h post 
transfection by measuring bioluminescence expressed in counts per second (cps) 
 
The critical surfactant concentration for spherical particle formation was found at  
0.5 % PVA for the first and 0.2 % PVA for the second solution. The influence of higher 
surfactant concentrations than needed for emulsion stabilization on particle size and 
transfection efficiency in the first aqueous solution is negligible. No differences in size 
between 0.5 and 4 % PVA could be observed. Only the particles with the lowest PVA 
concentration showed lower transfection efficiency than all the other tested specimens.  
Hence, 4 % PVA in the first aqueous solution was used as a standard to guarantee 
stable emulsions until the particle hardening process was completed to gain 
microparticles with optimal transfection efficiency. 
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A           B 
 
Fig. 14 – A) Particle size measurement of microparticles formed with different PVA concentrations in the 
second aqueous solution of the particle formation process. right: Transfection efficiency on rat bone 
marrow stem cells of microparticles formed with different PVA concentrations in the first aqueous solution 
of the synthesis process after 24 h post transfection. The reporter protein (metridia luciferase) activity was 
determined after 24 h post transfection by measuring bioluminescence expressed in counts per second 
(cps) 
 
An increase of PVA concentrations over the minimum for spherical particle formation 
did not lead to any trends in mean particle size either. Only particles made with 0.6 % 
PVA were slightly bigger in size than all other specimens. Protein production showed 
no significant trends for microparticles equilibrated in higher concentrations in the 
second aqueous solution. Particles formulated in 1 % PVA concentration in the second 
aqueous solution exhibited highest protein production. Hence, 1% PVA was used for 
further investigations and optimizations. 
  
Results 
43 
 
3.1.3 Influence of the energy input for phase interaction: sonication 
 
The interaction between the immiscible organic and aqueous phase is the basic 
requirement for microparticle formation based on a W/O/W solvent evaporation 
technique and therefore the encapsulation of the cargo. Sonication of the immiscible 
phases with a sonifier probe lead to reproducible particle formation and was chosen 
as energy source for phase interaction. In Fig. 15 results of size and transfection 
efficiency measurements for microparticles formed with different sonication energy 
input levels are depicted. 
 
A             B 
 
Fig. 15 – A) Particle size measurement of microparticles formed with different levels of sonication energy 
intensities. B) Transfection efficiency on rat bone marrow stem cells of microparticles formed with different 
levels of sonication energy intensities. The reporter protein (metridia luciferase) activity was determined 
after 24 h post transfection by measuring bioluminescence expressed in counts per second (cps) 
Microparticle size analysis showed hardly any differences between different sonication 
intensities from 37.5 to 125 V, except for one outlier result at 100 V where the particles 
turned out to be approximately 10 µm bigger in the mean. The mixing with different 
sonication intensities showed no substantial trends in transfection efficiency when in 
the same range of sonication intensities. The best performing particles in terms of 
transfection efficiency were formulated with 125 V. Hence, this setting was used for 
further investigations. 
Next to the intensity of the sonication at constant times of pulsing, the pulse length 
itself was investigated. Results for size and transfection efficiency measurements of 
particles formulated with pulses from 5 x 0.1 s to 1 x 5 s are displayed in Fig. 16. 
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A             B 
 
Fig. 16 – A) Particle size measurement of microparticles formed with different times of sonification pulses. 
B) Transfection efficiency on rat bone marrow stem cells of microparticles formed with different times of 
sonification pulses. The reporter protein (metridia luciferase) activity was determined after 24 h post 
transfection by measuring bioluminescence expressed in counts per second (cps) 
 
No substantial size differences or trends were observed between particles made with 
sonication pulses from 5 x 0.1 s to 1 x 5 s but transfection efficiency dropped drastically 
after increasing the pulse up to 5 s. Best protein production after 24 h post transfections 
was observed for particles made with 0.7 s pulses which is why this setting was used 
for further experiments.  
Additionally, exemplary particles exhibiting rather high and no transfection efficiency in 
vitro after their respective sonication process were scanned by SEM for potential 
visible damaging due to the process. Fig. 17, shows microparticles formulated with a 
sonication pulse time of 1s at 75 V representing well transfecting spheres and Fig. 18 
depicts microparticles formulated with a sonication pulse of 5 s at 75 V, representing 
spheres where no protein activity could be measured 24 h after transfection. 
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A             B 
  
Fig. 17 - Exemplary images of PLGA microparticles taken by scanning electron microscopy at a 
magnification of 2000. Microparticles were emulsified with a pulse time of 1 s at 75 V. 
 
A             B 
  
Fig. 18 - Exemplary images PLGA microparticles taken by scanning electron microscopy at a magnification 
of 2000. Microparticles were emulsified with a pulse time of 5 s at 75 V. 
All images displayed in both Fig. 17 and Fig. 18 disclose no considerable differences 
in topology, surface porosity or overall appearance. All particles display the typical 
porous surface and a spherical shape. Hence, the lack of transfection efficiency for 
particles emulsified with a 5 s pulse at 75 V intensity of sonication, cannot be explained 
by the shaping process of the microspheres. String-like structures can be observed in 
all SEM images.  
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3.1.4 Aqueous phase: cmRNA/lipid-complex 
 
The lipoplex loading of PLGA microparticles by emulsion solvent evaporation 
technique and its effects on the outcome of the product has not been described, so far. 
This is why lipoplex loading into the polymer matrix was investigated thoroughly in 
terms of possible effects on encapsulation efficiency, microparticle shape, size, surface 
topology and bio-functionality at different ratios of lipoplex to PLGA. Here, the lipoplex 
itself and its composition were kept constant which means that cmRNA to lipid contents 
is directly proportional. Hence, a new unit was introduced where the ratio of lipoplex to 
PLGA in microparticle formation could be described as µg RNA/mg PLGA.   
 
Lipoplex encapsulation efficiency in microparticles 
 
Encapsulation efficiency defines how much cmRNA was encapsulated during 
microparticle formation at different process parameters compared to a theoretical  
100 % loading. For measurement, it was crucial to release the RNA safely out of the 
polymer matrix without harming the cargo after the microparticles were lyophilized and 
in the form of a white powder. DMSO was used as the dissolving agent for the polymer 
matrix premixed with heparin sodium salt in water to displace the cmRNA out of the 
cationic lipids. The subsequent dispersion contained the free cmRNA, which could be 
quantified subsequently via RiboGreen Assay. Results of Table 2 and Fig. 19 show the 
results of encapsulation efficiency measurements of microparticles loaded between 
0.2 and 4 µg cmRNA/mg PLGA. For a better comprehension of this experiment a 
dotted line representing a theoretical 100 % encapsulation of the lipoplexes during 
microparticle formation, is shown. 
 
Table 2 - encapsulation efficiency of cmRNA in microparticles after formation, including theoretical loading 
parameters from 0.2 to 4 µg cmRNA/mg PLGA. 
 
 
100	%	encapsulation		[µg	cmRNA/mg	PLGA] 0.2 0.5 1 2 4
measured	encapsulation	[µg	cmRNA/mg	PLGA] 0.064 0.190 0.390 0.673 0.842
Standard	deviation	[µg	cmRNA/mg	PLGA] 0.002 0.021 0.019 0.007 0.040
lipoplex	loading	efficiency	[%] 32.10% 37.98% 38.96% 33.66% 21.06%
encapsulation	efficiency:
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Fig. 19 – Encapsulation efficiency of cmRNA in PLGA microspheres of batches produced with different 
nanoparticle to polymer ratios of 0.2 to 4 µg RNA/mg PLGA. The dotted line indicates a theoretical 
encapsulation of 100%.   
The measured results and the theoretical encapsulation at 100 % increasingly diverge 
from each other the more lipoplex was used for microparticle formation. Hence, the 
more lipoplex, which was initially used, the more lipoplex/cmRNA was eventually not 
encapsulated and lost in the washing process before lyophilization. The graph for the 
measured results increases logarithmically and plateaus between loading parameters 
of 2 to 4 µg RNA/mg PLGA. Here, a lipoplex saturation concentration could be 
indicated for these loading parameters.  
 
Microparticle size distribution by light microscopy and image analysis 
 
All microparticle mean sizes shown in this thesis were measured and analyzed via light 
microscopy image post-processing. It was possible to filter out broken, non-spherical 
particles from the analysis, which would not have been possible by i.e. light scattering 
methods. In Table 3 and Fig. 20. the comparison of the mean sizes of differently loaded 
microparticles discloses that from low to high loading ratios (0.2 to 4 µg cmRNA/mg 
PLGA) the particle mean becomes significantly smaller. The standard deviation for 0.2 
µg cmRNA/mg PLGA was rather high compared to all other examined microspheres 
with some particles exceeding the size of 120 µm.  
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Table 3 - mean particle size of PLGA microparticles with loading parameters from 0.2 to 4 m g cmRNA/mg 
PLGA. 
 
 
Fig. 20 - Particle size measurement of microparticles loaded with different nanoparticle to polymer ratios 
from 0.2.to 4 µg RNA/ mg PLGA. Diameters of particles were determined via post processing of images 
taken by light microscopy.  
Additionally, the particles made with loading parameters 0.5 and 1 µg cmRNA/mg 
PLGA exhibited lowest polydispersity with hardly any outlier particles above 40 µm. 
Here, the encapsulation of lipoplexes and the effect on the specific surface via mean 
particle size is similar to the effect, which certain surfactants can have on PLGA 
microparticle formation [63]. 
 
Surface topology investigation by SEM and image analysis 
 
Further analysis of particle powders revealed that besides the mean size of the 
microparticles, their surface topology is affected by nano-complex loading, as well. 
Examination of particles with a cmRNA loading of 0 µg - 4 µg cmRNA/mg PLGA by 
scanning electron microscopy (SEM) as displayed in Fig. 21, disclosed increased 
surface pore areas with decreased loading levels.  
loading	parameters	[µg	cmRNA/mg	PLGA] 0.2 0.5 1 2 4
Mean	particle	size	[µm] 28.90 23.04 20.53 19.07 14.10
Standard	deviation	[µm] 16.83 6.27 5.11 8.75 8.05
microparticle	size:
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A– 4 µg/cmRNA/mg PLGA        B – 2 µg/cmRNA/mg PLGA 
    
C – 1 µg/cmRNA/mg PLGA          D – 0.5 µg/cmRNA/mg PLGA 
    
E – 0.2 µg/cmRNA/mg PLGA          F – 0 µg/cmRNA/mg PLGA 
    
 
Fig. 21 – Exemplary images of PLGA microparticles taken by scanning electron microscopy at 
magnification of 3000, 2000 and 1000, respectively, for lipoplex loadings of A) 4, B) 2, C) 1, D) 0.5, E) 0.2 and 
F) 0 µg cmRNA/mg PLGA. 
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At 4 and 2 µg cmRNA/mg PLGA no surface porosity was visible. When no lipoplexes 
were used in the microparticle formation process, the spheres resemble sponge-like 
structures, which can be compared to microparticles made of Resomer® 502 H, 503 H 
or 504 H. The qualitative analysis of SEM images taken of particles with loadings 
between 0.2 and 1 µg cmRNA/PLGA showed string-like structures around the spheres. 
These cannot be found on the closed surfaces of microparticles loaded with 2 or 4 µg 
cmRNA/ mg PLGA. As a next step the black pore areas on the surfaces of the particles 
were quantified and divided by the total surface area visible on the images. The 
quantification results of the surface topology analysis are depicted in Fig. 22. 
 
 
Fig. 22 – Porosity measurement of microparticles loaded with different nanoparticle to polymer ratios from 
0 to 4 µg cmRNA/mg PLGA. Pore areas were divided by total particle surface area on scanning electron 
microscopy images to gain porosity quantification. 
Quantitative analysis of three SEM images for each loading parameter between 0.2 
and 4 µg cmRNA/mg PLGA show exponentially decreasing pore-to-total surface area 
ratios. No surface pores were measured for 2 and 4 µg cmRNA/mg PLGA in any of the 
images taken for surface topology analysis.  
 
Transfection efficiency investigation by metridia luciferase assay 
 
After the determination of the particles’ encapsulation efficiency, surface topologies 
and mean sizes, the spheres with different lipoplex loadings were compared for their 
transfection efficiency in vitro. In Fig. 23 transfection efficiency analysis of 
microparticles loaded with 0.2, 0.5, 1, 2 and 4 µg cmRNA/mg PLGA at two different 
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dosages, is displayed. Luminescence levels in supernatants were measured after 24, 
48, 72 and 96 h for 125 and 250 ng/well. The dose was determined by microparticle 
encapsulation efficiency analysis prior to the transfection. 
      A 
 
      B 
 
Fig. 23 - Transfection efficiency of microparticles loaded with different nanoparticle to polymer ratios from 
0.2 - 4µg cmRNA/mg PLGA on NIH3T3 mouse fibroblasts with different dosages for dosages of 2.5 and 5 
pg cmRNA/cell (125 ng and 250 ng/well). As controls, free lipoplexes and lipoplexes spiked to non-loaded 
microparticles were added to the cells at the same dosages. The reporter protein (metridia luciferase) 
activity was determined 24, 48, 72 and 96 h post transfection by measuring bioluminescence expressed in 
counts per second. 
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Generally, microparticle transfection efficiency is approximately one magnitude lower 
than those of free lipoplexes and free lipoplexes spiked on non-loaded microparticles 
at the same cmRNA dosages. Highest transfection efficiencies for free lipopolexes 
were measured at a dose of 125 ng/well after 24 h post transfection. At higher doses 
cytotoxicity may already have an effect on protein production. Only microparticles 
which were loaded with concentrations of 0.5 to 1 µg cmRNA/mg PLGA showed 
substantial transfection efficiency after 24 and 48 h for all dosages. Both levels dropped 
after a peak expression at 48 h after transfection. The luminescence trends over time 
are similar for both free lipoplexes and microparticles. 
In combination with the results from encapsulation efficiency experiments, a loading of 
0.5 µg cmRNA/ mg PLGA was chosen for further experiments. Although, those 
particles depict best transfection efficiency next to particles with a loading of  
1 µg cmRNA/mg PLGA, a loading of 0.5 is beneficial due to its higher efficiency in 
lipoplex encapsulation.   
 
3.2 Visualization of release of lipoplexes in vitro  
 
After having accomplished an optimized process for reproducible microparticle 
synthesis with subsequent transfection efficiency in the first days post transfection, the 
next goal was to investigate the lipoplex’s release behavior out of their polymer matrix 
in physiological fluids. For this purpose, spheres with 0.5 µg cmRNA/mg PLGA were 
formulated to qualitatively investigate the release mechanisms of the lipoplex bound in 
its matrix at different time points post transfection. The lipid component as well as 
cmRNA, were fluorescence labelled and encapsulated into microparticles for 
transfection on C2C12 mouse myoblasts. Those were utilized for this experiment, 
because they resemble later target cells as they are able to differentiate into 
osteoclasts [83]. The results of the fluorescence microscopy analysis are exhibited in 
Fig. 24. Here, images of microspheres (column A) and treated cells (column B) after 
transfection at time points from 0 to 96 h are displayed.  
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Fig. 24 - Exemplary images of microparticles on C2C12 murine myoblasts taken by fluorescence 
microscopy for qualitative cmRNA (red pixels) and lipid (green pixels) release and protein (white pixels) 
production visualization during the first four days after transfection. The scale bars represent a length of 
10µm. a) From top to bottom, the two columns show microspheres at time points from 0 to 96 h after 
transfection. The “mRNA” titled column displays encapsulated labeled cmRNA in microspheres in red 
pixels. The ”lipid” titled column displays encapsulated labeled DOPE in microspheres in green pixels.  
b) From top to bottom, the three columns display cells where the nucleus was stained and visualized by 
blue pixels at time points from 0 to 96 h after transfection. The “mRNA” titled column displays internalized 
labeled cmRNA around the cell nucleus in red pixels. The ”lipid” titled column displays internalized labeled 
DOPE around the cell nucleus in green pixels. The “protein” titled column displays recombinant protein 
produced in the cytosol accumulating over time in white pixels. 
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The distribution of cmRNA (red pixels) and lipid (green pixels) in microparticles over 
time reveals that a fraction of both components remains in the polymer matrix, even 
after four days of incubation under physiological conditions. Partial release and 
transfection of cmRNA could be observed via detection of labelled cmRNA (red pixels) 
in cells (blue pixels) starting as early as 16 h and lasting until 72 h. After that time point, 
no further cmRNA signal in cells could be found. Lipids (green pixels) were detected 
from 16 h to 96 h, mostly distributed around the cell nuclei. Recombinant protein (white 
pixels) accumulated in the cells from 16 h to 96 h with increasing signals during the 
first 72 h. To conclude, the transfection process from lipoplex release out of the 
microparticle matrix could be visualized, where not the microparticles themselves, but 
their cargo is taken up by the cells. After three days for cmRNA and four days for the 
lipids none of the signals could be detected in the cells, which indicates the end of an 
initial lipoplex release, where the rest of the cargo remains entrapped in the polymer 
matrix. 
 
 
3.3 Development of a composite ceramic/polymer bone substitute  
 
As the bioactive microparticles were developed for the enhancement of injectable bone 
substitute materials, the next step was to mix both the optimized polymer powder and 
the ceramic calcium phosphate (CaP) phase of an injectable bone substitute material. 
A well-established bone filling product (Calcibon®) was used for the experiments. In 
this chapter results for porosity enhancement and transfection efficiency of composite 
CPC/PLGA specimens, are presented. Ceramic to microparticle ratios were 
investigated via µ-CT analysis, followed by a transfection efficiency screen in vitro on 
mouse myoblasts. 
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3.3.1 µ-CT analysis of composite specimens for porosity analysis 
 
Optimized microspheres loaded with a lipoplex concentration of 0.5 µg cmRNA/mg 
PLGA were incorporated into injectable calcium phosphate cements. Here, the ability 
of the microparticles to increase the ceramic porosity after specimen curing was tested. 
Four specimens with four different weight-to-weight ratios of CPC to PLGA of 100:0, 
90:10, 80:20 and 70:30 were prepared. Those specimens were irregularly shaped, 
which made it necessary to determine defined volume fragments for each specimen to 
perform density comparison tests. Here, virtual discs with a diameter of 2 mm and the 
depth of 99 slices were determined and defined for analysis. Exemplary slices of the 
virtual discs, which were analyzed, can be seen in Fig. 25. From left to right specimens 
are depicted with an increase of microparticle phase to cement phase and a steady 
decrease in red pixels (cement phase) can be observed qualitatively. 3D rotational 
models after post processing via ImageJ are depicted in Fig. 26. Qualitatively the 
decline of ceramic phase (yellow fractions) from 0 % (w/w) of microparticles to 30 % 
(w/w) is apparent.  
 
 
Fig. 25 - Exemplary images of µ-CT slices displaying random parts of CPC/PLGA specimens of different 
weight to weight ratios. The weight to weight ratios depicted in A to D are 100/0, 90/10, 80/20 and 70/30 
calcium phosphate phase to pore phase (air and incorporated polymer microspheres), respectively. The 
cement phase is marked in red color. 
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Fig. 26 - Exemplary images taken from 3D rotation visualizations after the determination of a defined volume 
for density investigation. Ceramic high density parts are depicted in yellow for four different specimens: A) 
100 w% CPC. B) 90/10 w% CPC/PLGA. C) 80/20 w% CPC/PLGA. D) 70:30 w% CPC/PLGA 
In Fig. 27. the results of the greyscale analysis are depicted. Here volumes of cement 
phase divided by lower density volumes were quantified in the defined discs, which are 
illustrated in Fig. 26. 
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Fig. 27 - Pore volume to calcium phosphate cement volume ratio of four different CPC/PLGA weight to 
weight ratios. The ratio was calculated by macro programming of µ-CT voxels slides as can be seen in  
Fig. 25 
The calculated volume to volume ratios between the cement phase and the 
microparticle phase in the four different composites displayed an exponentially shaped 
increase in PLGA volume after the stepwise increase of CPC to PLGA weight to weight 
ratios. The non-linear course of the graph can be explained by the substantial 
difference in density between PLGA and cement.  
 
 
3.3.2 Transfection efficiency of composite and microparticle specimens 
 
Four CPC/PLGA composites as described above were additionally tested for their 
transfection efficiency in vitro. Protein production was measured over four days after 
transfection. Fig. 28 displays the results of those specimens, where bio-functionality 
was detected, and free PLGA microparticles with the same loading parameters were 
added to the experimental setup as a positive control. 
 
Results 
58 
 
 
Fig. 28 - Transfection efficiency of microparticles loaded with a nanoparticle to polymer ratio of 0.5 µg 
cmRNA/mg PLGA encapsulated in CPC in different weight to weight ratios on C2C12 mouse myoblasts. 
The doses for both free microparticles and components was 20 pg cmRNA/cell (1000 ng/well). The reporter 
protein expression (metridia luciferase) activity was determined 24, 48, 72 and 96 h post transfection by 
measuring bioluminescence expressed in counts per second (cps). 
Transfection efficiency analysis of the composite specimens with CPC/PLGA %(w/w) 
between 80:20 to 70:30 exposed similar bioluminescence levels as free microparticles 
in the first two days after transfection. After 3 days, protein production decreased for 
the composites compared to pure PLGA microspheres. In contrast to the transfection 
efficiency tests on mouse fibroblasts (Fig. 21), the protein production on mouse 
myoblasts (Fig. 26) after free microparticle transfection showed no significant drop 
after 4 days and peak expression was observed after 72 h. 
 
3.4 PLGA in nanoparticle carriers 
 
PLGA, as versatile as it is in various therapeutic approaches, is also known to stabilize 
and enhance polyplexes on a nanosize-level, i.e. in chitosan complexes [41, 42, 101]. 
In the second project of this thesis a novel polyplex containing chitosan for potential 
targets where mucosa barriers have to be crossed was developed. After successful 
nanoparticle formation with cmRNA and chitosan alone, co-formulation with PLGA was 
established, examined and optimized to gain possible polyplex enhancement in terms 
of biocompatibility, stability and transfection efficiency by this process. The goal of the 
Results 
59 
 
second part of this thesis was to explore the potential of chitosan-based cmRNA 
complexes, with and without PLGA, for their applicability in potential future in vivo trials. 
The reason for co-formulation with another polymer as an alternative to pure chitosan-
based polyplexes, is their lack of colloidal stability in physiological fluids, which 
challenged many chitosan-based nano-carrier related efforts in the last years [99-101]. 
For various different cargos, which have already successfully been encapsulated in 
chitosan-based nano-carriers, stabilizers like PEG or PLGA were additionally needed 
for successful in vivo functionality [102-104]. In this thesis, a comparison between 
chitosan- and co-formulated PLGA/chitosan polyplexes was conducted to determine 
the impact of co-formulation in physicochemical properties, especially the colloidal 
stability in a simulated physiological environment after optimizing the co-formulation 
itself.  
 
 
3.4.1 Chitosan nanoparticle development and characterization 
 
For this study Protasan® CL 113 UP, which is a water-soluble chitosan-chloride salt 
with a degree of deacetylation between 75 to 90 %, was used as the complexing agent 
for cmRNA, as it has already proven its potential as a complexing agent for DNA and 
other non-nucleic acid cargos [105, 106]. In a first trial, chitosan polyplexes with 
cmRNA coding for metridia luciferase were formed by pipetting and subsequent 
vortexing in N/P ratios of 0.5 to 10. In Fig. 29 size and zeta potential results for these 
particles, dispersed in water, are displayed. 
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Fig. 29 – Nanoparticle size and Zeta potential of chitosan polyplexes at N/P ratios of 0.5 to 10. The particles 
were mixed by pipetting and subsequent vortexing. 
The results of size analysis after 30 min of equilibration at room temperature show 
stable nanoparticles between 200 and 300 nm, except for N/P 2 where agglomeration 
was observed. Zeta potential analysis showed negatively charged particles at N/P 
ratios lower than 2 and a steady increase of surface charge in the range of 30 to 40 
mV for N/P ratios between 4 and 10. At N/P ratio of 2 no charge was observed.  
To investigate the polydispersity of the chitosan-based polyplexes the shapes of the 
size measurement graphs were examined, as well. Fig. 30 depicts the results of the 
size distribution measurements of all N/P ratios between 0.5 and 10.   
 
 
Fig. 30 - size distribution results from dynamic light scattering measurements in water of polyplexes 
characterized in Fig. 27.  
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Here, measurements for N/P 2 could not be detected as the agglomerates were either 
above the detection limit or no particles were formed in these conditions. All other 
specimens show a main peak at approximately 200 nm. Additionally, agglomeration 
peaks at sizes bigger than 1 µm and low sized peaks at sizes between 30 and 100 nm 
can be observed for specimens, with an N/P ratio higher than 6.  
Furthermore, gel electrophoreses was performed for polyplexes with N/P ratios from 1 
to 20, to investigate the chitosan’s ability to fully bind cmRNA at different polymer to 
nucleic acid ratios. An image of the gel is depicted in Fig. 31. 
 
 
Fig. 31 - Analysis of complex formation of chitosan (Protasan® CL UP 113) with cmRNA at N/P ratios of 1, 
2, 4, 8, 10, 15 and 20. Uncomplexed cmRNA (control) is displayed in lane 15. From right to left two lanes 
were reserved for one N/P ratio where the right lane (-) shows the results of untreated samples and the left 
lane (+) the results of complexes treated with heparin for 30 min at 70°C on a shaker. 
 
Only at N/P 1 unbound cmRNA was detected in line 14, where no heparin was applied 
to the sample. At higher N/P ratios no band of free cmRNA could be detected in the 
untreated samples indicating that all cmRNA is complexed with chitosan. After 
complexation, the interaction between carrier and cargo could be reversed by the 
addition of heparin to the dispersion in lanes 1, 3, 5, 7, 9, 11 and 13. 
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3.4.2 Screening of O/W emulsion mixing techniques 
 
As a next step the chitosan-based polyplexes were co-formulated with PLGA. In this 
project three different techniques were used for O/W emulsion formation. The first 
approach was a combination of osmotic mixing while the emulsion was stirred for 4 to 
24 h with subsequent emulsion mixing by an Ultra Turrax homogenizer. This approach 
was tested, using different organic solvents like ethyl acetate and dichloromethane at 
different homogenizer settings for 2 to 15 min. Here, all products lead to similar results 
in particle size distribution after organic solvent evaporation. In Fig. 32 an exemplary 
size distribution of a product after emulsification via Ultra Turrax homogenization is 
displayed.  
 
 
Fig. 32 - Exemplary size distribution of a PLGA/chitosan co-formulation polyplex after using an Ultra Turrax 
homogenizer for O/W emulsion formation. 
The particle distribution shows three particle size families where one peak is in the 
range of 1 µm, one in the range of approximately 100 nm and a small peak in the range 
of 20 nm.   
As it was not possible with this technique to form homogeneous particles, a second 
approach was anticipated where the interaction between the immiscible phases is 
triggered by sonication. Here, the parameters of pulse intensity, their repetition and the 
times between pulsing were screened. By using sonication techniques for 
emulsification, the reproducibility of the co-formulated PLGA/chitosan particle 
formation increased substantially and the product became homogenous in size as 
displayed in Fig. 33. 
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Fig. 33 - Exemplary size distribution of co-formulated PLGA/chitosan polyplexes after using a sonicator for 
emulsion formation.  
In this experiment different pulse lengths and repetitions were screened for potential 
polyplex optimization in terms of homogeneity of the hydrodynamic diameter. As all of 
the co-formulation parameters used for this experiment resulted in the same 
homogeneous particle distribution after polyplex preparation, no further optimization 
steps were needed for this method of emulsification. 
The results of the mean hydrodynamic diameter values and their respective zeta 
potential at different sonication pulses are shown in Fig. 34. 
 
 
Fig. 34 - Nanoparticle size and zeta potential of co-formulated PLGA/chitosan polyplexes at an N/P of 10. 
The O/W emulsion was mixed by sonication with a pulsing of 5 s at 6, 8 and 10 pulses and 2.5 s at 12, 16 
and 20 pulses, respectively. 
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Size and zeta potential analysis showed hardly any differences in the outcome of the 
product due to variations in pulsing but the resulting polyplexes did not show any 
transfection efficiency (data not shown). One possible reason for the lack in 
functionality could be a degeneration or disruption of cmRNA during the sonication. 
Therefore, this method for co-formulation was abandoned for further experiments. 
Even higher reproducibility in particle size was achieved by emulsification via 
microfluidic mixing. An exemplary result of a screening is shown in Fig. 35 where two 
different mixing setups in microtube arrangements were investigated. Here, a T-piece 
setup (Scheme 9 A) represents a two fluid mixing arrangement where the premixed 
aqueous phase is mixed in one point with the organic phase and the emulsion is 
discharged in an angle of 90 °. A Y-piece setup (Scheme 9 B) splits the aqueous phase 
into two fluids where the chitosan and cmRNA is initially separated from each other.  
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Scheme 9 – A) Schematic representation of the PLGA/chitosan/cmRNA-complex preparation process by 
microfluidic mixing in a “T-piece” setup. Chitosan polyplexes are mixed directly with the organic phase.  
B) Schematic representation of the PLGA/chitosan/cmRNA-complex preparation process by microfluidic 
mixing in a “Y-piece” setup. Chitosan polyplexes are mixed in a separate tubing before subsequently added 
to the organic phase.  
In a Y-piece setup the chitosan/cmRNA interaction and particle formation takes place 
immediately before the dispersion gets mixed to the organic phase. Both setups 
showed similar results in size and zeta potential as illustrated in Fig. 35. and first 
evidence of transfection efficiency in vitro (data not shown). The possibility of 
stabilizing the particle output by the addition of a buffer at a neutral pH was included 
into this pre-screening as well. 
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Fig. 35 - Nanoparticle size and zeta potential of co-formulated PLGA/chitosan polyplexes at an N/P of 10. 
The O/W emulsion was mixed by microfluidic mixings with either a T piece or a Y piece setup in either water 
or PBS as the diluent in the aqueous phase. 
 
Apart from a zeta potential drop to almost no charge, the influence of a PBS-buffered 
aqueous solution can be neglected concerning particle formation. Furthermore, several 
different injection speeds and injection volumes were optimized before a standard 
operating protocol for the synthesis of PLGA/chitosan particles could be implemented. 
As the T-piece setup resulted in less effort in synthesis setup and the resulting particles 
could be reproduced at a defined injection speed, this mixing technique became the 
standard operating procedure for further experiments. 
 
 
3.4.3 Screening of different PLGA polymers for the co-formulation  
 
After being able to define optimized synthesis protocols in terms of emulsion mixing 
and gaining reproducibility in polyplex particle size and zeta potential, the influence of 
PLGA polymer ratios to chitosan and the type of PLGA was screened for highest 
transfection efficiency. Three different PLGA types representing different 
hydrophilic/hydrophobic behaviors, due to their chemical structure, were formulated in 
a constant polymer weight per weight ratio of 1:10 chitosan/PLGA. Here only three 
different polymers were tested as each of those represents a certain class of 
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hydrophobic behavior. (3.1.1) Transfection efficiency results after co-formulation with 
each one representative of a lactic- to glycolic acid ratios (LA/GA) are displayed in  
Fig. 36.  
 
 
Fig. 36 - Transfection efficiency of co-formulated PLGA/chitosan polyplexes at an N/P ratio of 8 on NIH3T3 
mouse fibroblasts (600 ng cmRNA/well) formulated with different PLGA types. For all specimens the 
cmRNA encapsulation efficiency was determined before transfection.  cmRNA dosage was kept constant 
for all specimens during the experiment. The reporter protein (metridia luciferase) activity was determined 
24 h post transfection by measuring bioluminescence expression in counts per second (cps). 
Co-formulation with Resomer® 750 S, representing PLGA polymers with a LA/GA ratio 
of 7.5/2.5, resulted in particles with the highest protein activity after 24 h post 
transfection, followed by the more hydrophobic Resomer® 815 S and the rather 
hydrophilic Resomer® 502 H with an acid-terminated head-group. 
Furthermore, different ratios of 1:1, 1:62.5 and 1:125 (w/w) of chitosan to Resomer® 
750 S were tested for their influence on transfection efficiency after particle formation, 
as well. The results of this experiment are displayed in Fig. 37. 
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Fig. 37 - Transfection efficiency of co-formulated PLGA/chitosan polyplexes at an N/P ratio of 8 on NIH3T3 
mouse fibroblasts formulated with different chitosan to Resomer® 750 S weight to weight ratios. The 
reporter protein (metridia luciferase) activity was determined 24 h post transfection by measuring 
bioluminescence expression in counts per second (cps) 
In all dosages of cmRNA on cells from 500 to 2000 ng/well, highest protein activity 
could be measured for a polymer to polymer ratio of 1:62.5 (w/w). Hence, this polymer 
ratio was set as standard for further investigations. 
 
 
3.5 Investigation of co-formulation effects 
 
As a next step after the pre-screening of chitosan/cmRNA polyplexes, the impact of 
co-formulation with PLGA was investigated in detail. Here, the main focus was on the 
analysis of possible stability enhancements in physiological fluids and a direct 
comparison for cytotoxicity in vitro between both polyplex types.  
 
 
3.5.1 Polyplex size and zeta potential comparison 
 
First the effect of co-formulation with PLGA on the hydrodynamic diameter and zeta 
potential on the co-formulated particles was investigated. The results for size and zeta 
potential measurements are displayed in Fig. 38.  
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Fig. 38 – A) Hydrodynamic size and B) Zeta potential of chitosan- and PLGA/chitosan (62.5:1 w/w) 
polyplexes at N/P ratios of 1, 2, 4, 8, 10, 15 and 20. 
No significant size difference was observed for N/P ratios between 1 and 20 for both 
pure chitosan- and PLGA/chitosan polyplexes. Chitosan polyplexes agglomerate at 
N/P 2 with resulting particle diameters 1 ± 0.5 µm and beyond detection limits. This 
effect could not be observed for co-formulated particles at the same N/P ratio where 
the surface charge is negative. In general, PLGA/chitosan particles were slightly bigger 
compared to chitosan polyplexes except particles at N/P 2. 
In contrast to that, PLGA incorporation did not influence the surface charge of the 
nanoparticles. Generally, both chitosan-based and co-formulated PLGA/chitosan 
polyplexes, show a steady increase in surface charge from -11/-12 mV at N/P 1 to 
+25/+24 mV at N/P 10. From N/P 10 to 20 no further increase in zeta potential was 
measured for both polyplex types. The biggest difference between chitosan- and co-
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formulated PLGA/chitosan polyplexes in zeta potential was observed at N/P 2, where 
co-formulated particles show a negative surface charge compared to almost no charge 
for chitosan particles. 
 
 
3.5.2 Polyplex imaging via SEM 
 
Along with the results from size and zeta potential experiments the topological shape 
of the nanoparticles was investigated for any irregularities and differences between 
chitosan and co-formulated PLGA/chitosan polyplexes. Here, scanning electron 
microscopy was performed and exemplary images are depicted in Fig. 39. 
 
A       B 
                  
 
Fig. 39 - Exemplary images of A) chitosan and B) co-formulated PLGA/chitosan nanoparticles taken by 
scanning electron microscopy at a magnification of 50000. 
After qualitative observation and analysis of the images no significant differences in 
shape or agglomeration behavior were perceived. Both chitosan- and PLGA/chitosan 
polyplexes form clusters of particles and appear in a spherical shape. 
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3.5.3 Influence on complexation and particle stability 
 
The enhancement of colloidal stability and the ability to maintain integrity/compaction 
of the chitosan polyplexes in physiological fluids was one of the main goals of this 
project. The ability to protect the cargo in a physiological environment is critical for 
successful activity after transfection in vivo. Fluorescence resonance energy transfer 
(FRET) analysis was used as a measure for the compaction of cmRNA and therefore 
a good measure for particle stability. In Fig. 40 the compaction level of cmRNA 
complexed with either chitosan or co-formulated PLGA/chitosan polymer blends at N/P 
ratios of 8 and 15 in different amounts of PBS, is shown. 
 
 
Fig. 40 – FRET analysis over time of chitosan- and co-formulated polyplexes mixed with PBS measured at 
multiple time points between 8 min and 2 h. Nanoparticle dispersions were mixed with 20 %, 40 % and 60 
% of the test fluid. 
Here, all three concentrations of polyplex dispersion in PBS showed no substantial 
differences in compaction levels for each specimens over time. In every setting both 
co-formulated polyplex samples show approximately 3 times the FRET signal than free 
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cmRNA or chitosan/cmRNA polyplexes. N/P 15 signal exceeds the signal of N/P 8 
marginally in all settings. 
After determining the specimens’ stability in PBS the nanoparticles were analyzed after 
mixing with cell culture medium (DMEM). Results are shown in Fig. 41. 
 
 
Fig. 41 - FRET analysis over time of chitosan- and co-formulated polyplexes mixed with DMEM measured 
at multiple time points between 8 min and 2 h. Nanoparticle dispersions were mixed with 20 %, 40 % and 
60 % of the test fluid. 
The stability was measured after mixing the nanoparticle dispersions to three different 
concentrations of DMEM, which was used for in vitro experiments. For all 
concentrations of DMEM no compaction change over time was detected for any of the 
test dispersions. At 20 % DMEM, uncomplexed cmRNA shows higher FRET signals 
than chitosan/cmRNA polyplexes. This could be due to partly compaction by the 
ingredients of DMEM, like amino acids or different sugars. The same can be seen for 
40 % DMEM, as well. Both, in 20 and 40 % DMEM co-formulated PLGA/chitosan 
polyplexes showed stable but lower compaction over time, compared to the results 
measured for mixing with PBS. The compaction drops almost to the level of 
uncomplexed cmRNA at 40 % and cannot be distinguished at 60 %. 
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The third test fluid which was investigated was fetal calf serum (FCS) and stability 
results are depicted in Fig. 42. 
 
Fig. 42 - FRET analysis over time of chitosan- and co-formulated polyplexes mixed with FCS measured at 
multiple time points between 8 min and 2 h. Nanoparticle dispersions were mixed with 20 %, 40 % and 60 
% of the test fluid. 
Co-formulated PLGA/chitosan polyplexes showed again the best compaction levels at 
20 % of FCS. In contrast to measurements in DMEM and PBS, the high level of 
compaction decreases steadily over 2 h. Chitosan polyplexes showed again hardly any 
compaction, but slightly bigger compaction levels than uncomplexed cmRNA in all test 
settings. At 40 % serum the stability of co-formulated polyplexes decreased to the level 
of unclomplexed cmRNA much faster within about 30 min post mixing. At 60 % FCS 
the compaction values drop immediately after mixing to the level of uncomplexed 
cmRNA. To conclude, serum has the potential to lower the co-formulated polyplexes’ 
stability by steady erosion over time while chitosan/cmRNA complexes show hardly to 
any compaction in all settings. 
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To conclude, FRET analysis revealed that chitosan-based particles showed little 
complexation compared to uncomplexed cmRNA and no substantial stabilization in all 
tested media. In contrast, FRET analysis indicated a substantial increase in cmRNA 
compaction for co-formulated PLGA/chitosan particles for all N/P ratios in all test 
media. In general, complexation was higher for N/P 15 compared to N/P 8 in the case 
of co-formulated particles.  
 
 
3.5.4 Influence of co-polymerization on cytotoxicity  
 
Apart from being functional and stable in physiological fluids, carrier systems for 
nucleic acids are desired to be as non-toxic and biocompatible as possible to gain a 
relatively wide therapeutic efficacy. Therefore, biological functionality and cytotoxicity 
comparisons between chitosan- and co-formulated PLGA/chitosan polyplexes were 
conducted side-by-side. In Fig. 43 MTT assay measurements for chitosan-based 
polyplexes are shown. 
 
Fig. 43 - MTT assay results for chitosan polyplexes on NIH3T3 mouse fibroblasts. The results are 
normalized to untreated cells which were seeded on the respective plates. N/P ratios of 8, 10 and 15 were 
analyzed. 
In the case of pure chitosan polyplexes toxicity is prominent already at very low doses. 
Almost no cell viability can be observed from 1.5 µg cmRNA/well and higher. Below 
1.5 µg cmRNA/well the toxicity is proportional to the N/P ratio and therefore the polymer 
content. The more polymer which was added to the transfection media, the lower the 
cell viability was identified after 24 h.  
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In the same experiment co-formulated PLGA/chitosan polyplexes at the same N/P 
ratios were tested for their biocompatibility and the results are shown in Fig 44. 
 
 
Fig. 44 - MTT assay results for co-formulated PLGA/chitosan polyplexes on NIH3T3 mouse fibroblasts. The 
results are normalized to untreated cells which were seeded on the respective plates. N/P ratios of 8, 10, 
and 15 were analyzed. 
In contrast to chitosan/cmRNA complexes, cells transfected with co-formulated 
PLGA/chitosan polyplexes exhibit high cell viability, even at high doses after 24 h post 
transfection. Here, no trends in N/P ratio comparison can be observed and cell viability 
never declines below approximately 80 %. All in all, the PLGA/chitosan polyplexes can 
be labelled as non-toxic in the given experimental setup. The negligible decline in cell 
viability for all N/P ratios at 6000 ng cmRNA/well was accounted to fluctuations of MTT 
signal depending on the position of the respective well plate. 
 
 
3.5.5 Influence on transfection efficiency 
 
The high level of biocompatibility of co-formulated PLGA/chitosan polyplexes was 
observed in the experiment results of the transfection efficiency tests, as well. In  
Fig. 45 A, a visualization of the transfection process for co-formulated particles is 
displayed.  
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Fig. 45 – Exemplary images of NIH3T3 mouse fibroblasts taken by fluorescence microscopy. The scale bar 
represents a length of 10 µm. The nuclei are displayed in blue-, cmRNA in red- and recombinant protein 
developed via transfection in green color. A) The image was taken after 24 h post transfection and the cells 
were treated with water. B) The image was taken after 24 h post transfection and depicts cells transfected 
with co-formulated PLGA/chitosan polyplexes at an N/P ratio of 15. The dose was 1µg cmRNA/well. 
 
In the exemplary image of cells 24 h after transfection with co-formulated polyplexes 
the red dots indicate internalized cmRNA in the cytosol and the recombinant protein in 
green color after successful translation. The quantification of protein activity after 24 h 
post transfection of both chitosan- and co-formulated PLGA/chitosan polyplexes is 
depicted in Fig. 46. Here the luciferase activity was measured for dosages between 47 
and 6000 ng cmRNA/well for both chitosan- and co-formulated PLGA/chitosan 
polyplexes at N/P ratios of A) 8, B) 10 and C) 15. 
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Fig. 46 - Transfection efficiency of chitosan and co-formulated PLGA/chitosan polyplexes at N/P ratios of 
8, 10, and 15 on NIH3T3 mouse fibroblasts. The reporter (metridia luciferase) activity was determined 24 
post transfection by measuring bioluminescence expressed in counts per second (cps). 
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Chitosan polyplexes exhibit peak expression at N/P 8 and decrease with increasing 
N/P ratio. The shift of peak expressions to lower dosages can be accounted to the 
efficiency and the toxicity of the chitosan. Peak expression with following decline in 
luminescence at higher dosages for co-formulated PLGA/chitosan nanoparticles was 
only perceived at N/P 15 where it exceeds the luminescence levels of chitosan 
polyplexes. In contrast to chitosan polyplexes the peak expression shifts to higher 
dosages with increasing N/P ratios. 
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Discussion 
 
The results of both micro- and nanoparticle experiments demonstrate the 
biocompatibility and the validity of poly (lactic-co-glycolic acid) as a carrier agent in the 
field of chemically modified messenger RNA delivery. On the one side, the polymer 
was successfully used as a matrix polymer for the incorporation and immobilization of 
lipoplexes containing cmRNA, with the ability to release its cargo when put into 
aqueous solutions. These functionalized microparticles were successfully incorporated 
into calcium phosphate (CaP) cements to form injectable composites with the potential 
of transfecting cells at site.  
On the other side, PLGA enhanced chitosan/cmRNA polyplexes as a stabilizer with 
direct impact on cytotoxicity, transfection efficiency and the compaction ability of a 
chitosan-based polyplex.  
  
3.6 PLGA microparticles as a lipoplex distribution system  
 
In the first part of this thesis the incorporation of a functional cmRNA delivery system 
into injectable calcium phosphate-based cements was investigated. Early pre-
screening results revealed a requirement for an intermediate phase between 
lipoplexes and calcium phosphate cement, as direct mixing did not result in any bio-
functional activity. The lipoplexes were encapsulated into spherical PLGA matrices to 
provide the ability to immobilize the cmRNA carriers in the cements and release the 
bio-functional carrier at site. It was already discovered that the combination of CPC 
and PLGA microparticles conveys benefits in bone substitute degradation and cell in-
growth into the implant in the healing process [58, 76, 77]. In this study the idea was 
to enhance this approach by the incorporation of a bio-functional agent in the form of 
cmRNA/lipoplexes into such microparticles with the potential of increasing faster bone 
healing by i.e. the introduction of growth factors, at site. 
The formation process of the microparticles needed to be adjusted and optimized for 
an initial lipoplex release which leads to immediate transfection efficiency after contact 
with aqueous fluids. Results showed that it is possible to encapsulate lipoplexes into 
degradable polymer microspheres by a double emulsion solvent evaporation technique 
without destroying the complexes’ functionality, but early experiments resulted in either 
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broken or too big microparticles. It was important to define a standard operating 
procedure for the formation process which provides reproducibility in size and 
efficiency. Using different Resomer® PLGA types for lipoplex encapsulation revealed 
the influence of the polymer’s chemical properties on the ability to form appropriate 
microparticles. Resomer® 502H, 503 H, and 504 H which represent the most 
hydrophilic polymers used in these experiments, due to their GA/LA ratio of 1/1 and 
their acidic terminations, showed lowest transfection efficiency and biggest mean sizes 
with a sponge-like microparticle appearance. Their geometrical features resemble 
those of non-loaded particles, which indicated that these polymers were not able to 
successfully encapsulate the lipoplex cargo. Therefore, these polymers were excluded 
from any further experiments. An optimal encapsulation - to transfection efficiency 
balance was found by using polymers which presented comparably moderate to high 
hydrophobicity like Resomer® 750 S, 752 S, 755 S and 858 S. The hydrophobicity 
favors interaction of the lipoplex as proposed by the distributor [107]. Here, Resomer® 
750 S was defined as the polymer of choice for further experiments due to best 
transfection efficiency results and a rather high reproducibility in particle formation.  
Next, the influence of varying the surfactant concentrations in both the first and second 
aqueous phase of the particle formation protocol was investigated. For both aqueous 
solutions it was shown that as long as a minimum surfactant concentration for avoiding 
emulsion collapse was met, the surfactant concentration itself did not have any obvious 
effect on both size and transfection efficiency. In contrast, the emulsification process 
by different sonication protocols via a sonfier probe revealed a drastic drop in 
transfection efficiency, when the pulsing time of sonication and therefore the input 
power is exceeding an optimal process limit. As, in this case, no obvious effect on 
particle size and topology compared to particles made with lower sonication pulse 
times was detected, it is likely that the cargo itself was damaged or even destroyed by 
an excess of power input by sonication.  
Varying the nanoparticle concentration during microparticle formation had the highest 
capacity to adjust the microparticles’ size, topology and transfection efficiency. It was 
possible to optimize the ratio between lipoplex concentration in the first aqueous phase 
and a constant amount of PLGA in the organic phase to gain highest protein production 
levels after in vitro transfection. Here, a correlation between the specific surface of the 
microparticles and their ability to transfect cells was found. Highest protein production 
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occurred with particles, which exhibited relatively small particle sizes and rather high 
surface pore areas. The initial swelling of the microparticles which enables an initial 
diffusion of lipoplexes encapsulated on the surface, is favored at high specific surface 
areas. Hence, more lipoplex is initially released which leads to optimal transfection 
efficiency. This observation corresponds with literature about other PLGA-
microparticle-based release systems, stating that controlling the specific surface of the 
microparticles is crucial for the control over release behavior of the cargo at hand [98, 
99]. 
Consequently, an interval of lipoplex loading parameters between 0.5 and  
1 µg cmRNA/mg PLGA was determined where the product exhibited a maximum of 
transfection efficiency. Encapsulation efficiency analysis for these two loading 
parameters revealed higher loss of educt (lipoplex) during the formation process for 1 
µg cmRNA/mg PLGA with similar transfection efficiency as 0.5 µg cmRNA/mg PLGA. 
Therefore, and with the aim of efficiently and economically optimizing particle formation 
parameters, the decision was made to continue the study with a particle loading 
parameter of 0.5 µg cmRNA/mg PLGA. 
Via fluorescence microscopy and lipoplex labelling it was possible to visualize the 
process of lipoplex release from the microparticle matrix during the first 4 days after 
transfection. The signal for both cmRNA and lipid contents was detected in the 
microparticles, as well as in the surrounding cells. In this experiment, a burst release 
of lipoplex which lead to the internalization of both lipids and cmRNA in cells was 
detected, while a second fraction of cargo was still entrapped in the polymer matrix 
after 4 days under simulated physiological conditions in vitro. The lipoplex fraction 
which was released was able to transport the cmRNA into the cytosol where it was 
successfully translated into the encoding protein. Different independent PLGA 
microparticle studies revealed similar patterns for an initial diffusion of cargo out of the 
matrix. Depending on the PLGA type and the physicochemical features of the cargo 
an initial burst release is often followed by a slow release via polymer erosion [97-99]. 
Furthermore, the results disclosed that cmRNA is cleared faster from the cytosol as 
their lipid counterparts which could be detected even after 4 days after transfection. 
As a next step the optimized particles were incorporated into CPCs to investigate their 
potential in combination with the injectable bone substitute. 
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3.7 PLGA microparticles as composite in injectable calcium phosphate 
cements 
 
The incorporation of lipoplex loaded PLGA microspheres into calcium phosphate-
based injectable cements resulted in composite specimens with an adjustable porosity. 
The weight to weight ratio of calcium phosphate (CPC) phase and PLGA polymer 
phase was adjusted successfully to control cement porosity in the composite after 
curing. As the densities between cement and polymer phases differ substantially, the 
impact of increasing polymer volume could be visualized via computer tomography. 
The porosity quantification results showed an exponential increase in low density 
polymer/air phase when the weight to weight ratio of PLGA to CPC was gradually 
increased. The exponential nature of the increase of polymer volume in the specimens 
is associated with the substantial differences in density between the two phases of the 
composite. At ratios lower than 70:30 (cement/polymer) % (w/w) the specimens lost 
their integrity after hardening which disqualified them from further investigations. 
Depending on the % (w/w) ratio of CPC to PLGA we could show that lipoplexes were 
still released out of the polymer/cement matrix which resulted in positive transfection 
of target cells in vitro. Transfection efficiency analysis via bio-luminescence 
measurements revealed similar results for particles compacted in the cement matrix 
and free microparticles at cement to polymer ratios lower than 90:10 % (w/w) after 24 
h. The decline in protein production after 48 h could be explained by the limited surface 
area of microparticles which could directly swell at the presence of aqueous fluids. 
 
 
3.8 The enhancement of chitosan/cmRNA complexes by co-formulation 
with PLGA 
 
In the second part of this thesis the first aim was to investigate the capacity of chitosan 
for cmRNA compaction and complexation. We confirmed that chitosan is able to bind 
negatively charged cmRNA due to its deacetylated state, where free amines provide 
the positive charge. But the resulting polyplexes resulted in labile nanoparticles with 
hardly any compaction and stability in physiological fluids like DMEM or serum which 
was observed by FRET analysis. This lack of stability was observed in other studies 
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dealing with chitosan as a carrier system for nucleic acids [102] and could be due to 
its chemical structure. Compared to other well-investigated polyplex agents like 
branched polyethyleneimine (brPEI) the polymer itself is elongated and has only one 
primary amine per deacetylated monomer. In contrast brPEI exhibits a network or 
interacting primary-, secondary and tertiary amines which together form a dense 
network of positive charges (charge per weight for brPEI: 1:43 x 1/g/mol; for chitosan: 
1:190 x 1/g/mol) [28, 108]. Hence, the focus was placed on the enhancement of 
chitosan/cmRNA polyplexes by the co-formulation with PLGA in terms of cmRNA 
compaction and stability in physiological fluids. For this purpose, PLGA was 
incorporated via a solvent evaporation technique again with interface interaction 
between the chitosan polyplex dispersion and an organic phase containing the polymer 
in the presence of PVA as the emulsion stabilizer. The adjustment of the co-formulation 
process in terms of the emulsification process and the optimal composition of chitosan 
to PLGA polymer led to reproducible polyplex formation. Especially using the highly 
controlled method of microfluidic mixing for interphase co-formulation showed high 
reproducibility in size and efficiency due to the controlled adjustability of process 
parameter [109, 110]. The main difference of both double emulsion solvent evaporation 
techniques in the microparticle formation as described above and the nanoparticle co-
formulation was the optimization of the energy input to the respective emulsions. Here, 
it was possible to form nano-sized co-formulations with an incorporation of PLGA to 
the chitosan polyplex due to fine tuning of the microfluidic mixing. Due to these 
standard operating procedure modifications for PLGA co-formulation, an investigation 
of the effects of co-formulation on the nanoparticles’ properties was made possible. It 
was not possible to confirm any incorporation of PLGA into chitosan polyplexes directly 
by chemical analysis but comparisons to chitosan polyplexes in terms of 
physicochemical properties, colloidal stability in physiological fluids, biocompatibility 
and transfection efficiency indirectly showed differences in particle behavior.  
First size comparisons were conducted which revealed that co-formulation made the 
nanoparticles slightly bigger in hydrodynamic diameter, even though obvious 
differences in the surface or spherical shape could not be detected. Zeta potential 
analysis revealed no substantial differences between chitosan- and PLGA/chitosan 
polyplexes at different N/P ratios. Hence, in contrast to shielding processes such as 
PEGylation, the zeta potential could be maintained although another agent was 
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introduced to the nanoparticle structure [104, 111]. These results indicate that PLGA 
was incorporated into the nanoparticles without shielding the positive charges derived 
from chitosan.  
Furthermore, it was demonstrated that the degree of compaction was considerably 
increased after co-formulation of chitosan/cmRNA complexes with PLGA. Co-
formulation enabled protection from destabilization in physiological media comprising 
FCS, including increased stability in cell culture medium and PBS. Compaction of 
cmRNA analysis via FRET analysis also revealed a steady increase in stability in all 
test media from low to high N/P. FRET analysis revealed the PLGA’s capacity to 
increase the colloidal integrity of chitosan/cmRNA complexes, which possibly prevents 
premature particle decomposition in future in vivo applications. In summary, 
chitosan/cmRNA composites can be successfully complemented by PLGA addition, 
which results in enhanced compaction and protection of the cargo without changing 
the surface charge. PLGA/chitosan polyplexes exhibit substantially higher colloidal 
stability in simulated physiological conditions than chitosan/cmRNA complexes alone.  
The effects of co-formulation were also observed in the analysis of transfection 
efficiency and cytotoxicity on mouse fibroblasts. The trends in cell viability in 
combination with transfection efficiency revealed a rather narrow dosing window for 
chitosan-based nanocomplexes. The decrease of protein production and therefore the 
transfection efficiency correlates with a decrease in cell viability, meaning an increase 
in toxicity. The higher the N/P ratios, the more the peak expression shifted to lower 
dosages of cmRNA on cells.  
In contrast, no substantial cell toxicity at any dosage could be observed for 
PLGA/chitosan particles at all tested N/P ratios. The transfection results demonstrated 
functionality at high dosages with even higher peak luminescence levels as chitosan 
polyplexes. Therefore, the positive charge of chitosan polyplexes cannot be 
determined as the main reason for cytotoxicity, as the co-formulated particles with 
PLGA exhibited comparable charge properties. Hence, the increase in cell viability 
after transfection for co-formulated polyplexes is solely due to the properties of PLGA 
and its co-formulation to the polyplexes. The shift to higher dosages to achieve high 
levels of protein production for co-formulated particles could be attributed to the 
PLGA’s chemical behavior in aqueous fluids, as well. Due to its rather hydrophobic 
character, delayed hydrolysis takes place over time [60]. This could lead to a delay in 
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cmRNA translation at a certain point during cell uptake or the release from the carrier 
in the cytosol. Similar delays could be observed in PLGA-based nanocomplexes 
encapsulating various other cargos [79, 112]. Although we could show a substantial 
enhancement of complexation in vitro by co-formulation with PLGA, which preserved 
functionality of chitosan-based polyplexes, further studies in more complex 
environment like body fluids will need to be addressed. Most likely, the full potential of 
the co-formulated polyplexes in terms of colloidal stability and bio-functionality in 
physiological conditions can only be evaluated in further detailed in vivo studies. 
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Summary 
 
Both projects in this thesis aimed at finding strategies which make cmRNA biologically 
available via different application routes, by using the biopolymer PLGA as either 
matrix- or stabilization agent. cmRNA as one of the most promising approaches in 
transcript therapy bears the potential of treating diseases which cannot be treated until 
today. Combining such a polymer with its versatility and adjustability, which has been 
proven in various trials in different fields of drug delivery with the rather new cmRNA 
technique was therefore the aim of this project. 
In the first study the focus was set on the incorporation of cmRNA/lipid system into a 
calcium phosphate cement system to potentially improve bone healing using transcript 
therapy. The production of i.e. growth factors by cmRNA transfection at site for new 
bone formation in combination with an injectable stabilization agent was set as the 
main goal of this study. The ability to directly inject a transfecting product into bone 
defects which in itself resembles natural bone, while maintaining a certain mechanical 
strength, is highly desirable for patients in need of surgical treatments like i.e. 
kyphoplasty or even vertebroplasty. The main task was to find a strategy which enabled 
the incorporation of a cmRNA carrier system in the cement phase which is able to 
release the cargo after implantation. This was done by circumventing the direct 
incorporation of the lipoplex into the hardly biodegradable cement phase by adding a 
biodegradable polymer phase which enables lipoplex release in combination with a 
porosity increase in the cement matrix. After the proof of concept for lipoplex 
incorporation into the microparticle matrix, and the microspheres’ synthesis 
optimization, it was possible to successfully incorporate the polymer phase into CaP-
based injectable cements for bone defect filling simulation in vitro. Even though the 
cmRNA was compacted into a lipoplex which was incorporated into a polymer matrix 
which itself was incorporated into injectable cement, biological functionality was 
maintained and demonstrated. As a next step these specimens need to be tested for 
long-term release kinetics and biocompatibility before they can be tested in vivo.  
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In the second project PLGA was not used as a matrix for the nanocarriers of cmRNA 
but as the compaction agent itself in combination with the amine-bearing polymer 
chitosan. Next to lipid-based vectors, polyplexes are a valid and desirable alternative 
for the compaction and transfection of nucleic acids. Chitosan as a biopolymer itself 
was already used in many different approaches of drug- and nucleic acid therapy but 
lacked sufficient ability to compact and stabilize the cargo in physiological conditions. 
The idea at hand was combining the chitosan’s ability to bind nucleic acids and the 
PLGAs stabilizing properties for cmRNA compaction and delivery, especially because 
both polymers show high biocompatibility. We showed that chitosan alone is, in fact, 
able to bind cmRNA successfully and to transfect fibroblasts in vitro, but high 
cytotoxicity and low colloidal stability lowered the material’s potential for cmRNA 
delivery drastically. For co-formulation with PLGA the operating protocol was optimized 
before the impact of co-formulation could be analyzed and investigated. Co-formulation 
led to physicochemical changes in the polyplexes which eventually led to a higher 
complexation potential with reduced bio-functionality while showing hardly any 
cytotoxicity. These findings bear the potential for an alternative strategy to already well-
established carrier systems like br-PEI polyplexes or lipoplexes in general, which are 
known to be toxic, immunogenic and are hardly biodegradable. On the other hand, the 
PLGA/chitosan polyplexes have only proven their potential in vitro so far. Only future 
in vivo trials in highly complex fluids and obstacles for successful cell transfection in 
lungs like mucus barriers can reveal the potential of this new approach for polyplex-
based cell transfection.  
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5 Appendix 
5.1 Abbreviations 
 
PLGA poly(lactic-co-glycolic acid 
RNA ribonucleic acid 
DNA deoxyribonucleic acid 
cmRNA chemically modified messenger RNA 
siRNA small interfering RNA 
pDNA plasmid DNA 
FRET fluorescence resonance energy transfer 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid 
SEM scanning electron microscopy 
µ-CT micro-computer tomography 
O/W/O oil in water in oil emulsion 
O/W oil in water emulsion 
TLR toll-like receptor 
s2U/U 2-thio-uridine/uridine 
i.e. id est 
EPO erythropoietin 
hBMP-2 human bone morphogeneic protein- 2 
et al. et alii 
DOPE (1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine 
PEG poly(ethylene glycol) 
LA lactic acid 
GA glycolic acid 
Mw molecular weight 
PVA poly(vinyl alcohol) 
DMSO dimethylsulfoxide 
DCM dichloromethane 
WFI water for injection 
PBS phosphate-based saline 
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CaP calcium phosphate 
DMEM dulbecco’s modified eagle medium 
EDTA ethylenediaminetetraacetic acid 
Pen/Strep penicillin streptomycin 
FBS fetal bovine serum 
FCS fetal calf serum 
GFP green fluorescent protein 
HCl hydrochloric acid 
ISO international organization of 
standardization 
DLS direct light scattering 
rBMSC rat bone marrow stem cell 
NIH3T3 National institute of health, mouse 
fibroblast line 
C2C12 mouse myoblast line 
DBCO dibenzocyclooctyne 
DMG-PEG 2k diacylglycerol poly(ethylene glycol); 
Mw= 2000 kD 
kD kilo Dalton 
N/P nitrogen to phosphate 
UK United Kingdom 
Fig. Figure 
3D three dimensional 
brPEI branched polyethyleneimine 
rpm rotations per minute 
TRIS tris(hydroxymethyl)aminomethane 
Cy cyanin 
% (w/w) weight to weight ratio in percent 
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5.2 Publications 
 
Publications as a first author: 
 
cmRNA/lipoplex encapsulation in PLGA microspheres enables transfection via calcium 
phosphate cement (CPC)/PLGA composites (Utzinger, Jarzebinska, Haag, Schweizer, 
Winter, Dohmen, Rudolph, Plank. - Journal of Controlled Release – 2016) PMID: 
28161466) 
 
Co-formulation of chitosan/cmRNA complexes with PLGA enhances biocompatibility 
and nucleic acid compaction (Utzinger, Beck, Winter, Dohmen, Rudolph, Plank, 
International Journal of Nanomedicine – submitted) 
 
Publications as second author: 
 
Chemically modified RNA induces osteogenesis of stem cells and human tissue 
explants as well as accelerates bone healing in rats (Balmayor, Geiger, Aneja, 
Berezhanskyy, Utzinger, Mykhaylyk, Rudolph, Plank – Biomaterials – 2016) PMID: 
26923361 
 
Transcript-activated collagen matrix as sustained mRNA delivery system for bone 
regeneration (Badieyan, Berezhanskyy, Utzinger, Aneja, Emrich, Erben, Schüler, 
Altpeter, Ferizi, Hasenpusch, Rudolph, Plank – Journal of Controlled Release – 2016) 
PMID: 27586186 
 
Patents: 
 
Compositions for introducing nucleic acids into cells of the gastrointestinal tract 
(Dohmen, Utzinger, Hasenpusch, Rudolph, Plank – Ethris GmbH - 06.02.2014 - 
WO2015/128030 A1)  
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5.3 Supplementary information 
 
Macroinstruction for the automatic analysis of microparticles mean sizes by image post 
processing via ImageJ: 
 
run("Clear Results"); 
 
dir = getDirectory("Choose a Directory"); 
list = getFileList(dir); 
for (i=0; i<list.length; i++) { 
 path = dir+list[i]; 
 if (endsWith(path, ".jpg")) { 
open(path); 
name=getTitle; 
run("Set Scale...", "distance=2313 known=1000 pixel=1 unit=µm global"); 
makeRectangle(2115, 1683, 405, 195); 
setBackgroundColor(255, 255, 255); 
run("Clear", "slice"); 
run("8-bit"); 
 
run("Select None"); 
 
setAutoThreshold("IsoData"); 
setThreshold(50, 110); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
 
run("Watershed"); 
run("Fill Holes"); 
run("Dilate"); 
run("Fill Holes"); 
run("Watershed"); 
run("Fill Holes"); 
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run("Watershed"); 
run("Fill Holes"); 
run("Set Measurements...", "  perimeter feret's limit redirect=None decimal=3"); 
run("Analyze Particles...", "size=50-8000 circularity=0.5-1.00 show=Nothing 
exclude add"); 
roiManager("Measure"); 
waitForUser; 
 
run("Close All"); 
} 
} 
roiManager("Delete"); 
saveAs("Results", dir + "Resultsnew.txt"); 
 
Macroinstruction for the automatic definition of CPC/PLGA specimens investigated for 
porosity by image post processing via ImageJ: 
 
makeOval(375, 396, 244, 244); 
makeRectangle(256, 132, 350, 341); 
 
 
 
 
 
 
 
 
Macroinstruction for the automatic image post processing of fluorescence microscopy 
images via ImageJ for microparticle investigation: 
 
 
dir = "C:\\” 
list = getFileList(dir); 
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for (i=0; i<list.length; i++) { 
 
 
if (endsWith(list[i], "+++518/")) { 
 
open(dir + list[i] + "protein.tif"); 
run("8-bit"); 
setThreshold(3,255); 
run("Create Selection"); 
run("Multiply...", "value=30"); 
run("Select None"); 
resetThreshold(); 
 
open(dir + list[i] + "mRNA.tif"); 
run("8-bit"); 
setThreshold(3,255); 
run("Create Selection"); 
run("Multiply...", "value=5"); 
run("Select None"); 
resetThreshold(); 
 
open(dir + list[i] + "DNA.tif"); 
run("8-bit"); 
setThreshold(2,255); 
run("Create Selection"); 
run("Multiply...", "value=5"); 
//run("Add...", "value=50"); 
run("Select None"); 
resetThreshold(); 
 
run("Merge Channels...", "c1=mRNA.tif c4=protein.tif c3=DNA.tif create keep"); 
rename(list[i] + " composite"); 
run("Set... ", "zoom=50 x=696 y=520"); 
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close("mRNA.tif"); 
close("protein.tif"); 
close("DNA.tif"); 
 
 
}; 
 
if (endsWith(list[i], "++519/")) { 
 
open(dir + list[i] + "lipid.tif"); 
run("8-bit"); 
setThreshold(4,255); 
run("Create Selection"); 
run("Multiply...", "value=3"); 
run("Select None"); 
resetThreshold(); 
 
open(dir + list[i] + "mRNA.tif"); 
run("8-bit"); 
setThreshold(2,255); 
run("Create Selection"); 
run("Multiply...", "value=5"); 
run("Select None"); 
resetThreshold(); 
 
open(dir + list[i] + "DNA.tif"); 
run("8-bit"); 
setThreshold(2,255); 
run("Create Selection"); 
run("Multiply...", "value=5"); 
//run("Add...", "value=50"); 
run("Select None"); 
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resetThreshold(); 
 
run("Merge Channels...", "c1=mRNA.tif c2=lipid.tif c3=DNA.tif create keep"); 
rename(list[i] + " composite"); 
run("Set... ", "zoom=50 x=696 y=520"); 
 
close("mRNA.tif"); 
close("lipid.tif"); 
close("DNA.tif"); 
 
}; 
 
if (endsWith(list[i], "520/")) { 
 
open(dir + list[i] + "lipid.tif"); 
run("8-bit"); 
setThreshold(5,255); 
run("Create Selection"); 
run("Multiply...", "value=3"); 
run("Select None"); 
resetThreshold(); 
 
open(dir + list[i] + "protein.tif"); 
run("8-bit"); 
setThreshold(4,255); 
run("Create Selection"); 
run("Multiply...", "value=30"); 
run("Select None"); 
resetThreshold(); 
 
open(dir + list[i] + "DNA.tif"); 
run("8-bit"); 
setThreshold(2,255); 
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run("Create Selection"); 
run("Multiply...", "value=5"); 
//run("Add...", "value=50"); 
run("Select None"); 
resetThreshold(); 
 
run("Merge Channels...", "c2=lipid.tif c3=DNA.tif c4=protein.tif create keep"); 
rename(list[i] + " composite"); 
run("Set... ", "zoom=50 x=696 y=520"); 
 
close("protein.tif"); 
close("lipid.tif"); 
close("DNA.tif"); 
 
}} 
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5.3.1 Supplementary Information to 2.3.9 µ-CT analysis of composites 
 
Fig. 47 - Schematic representation of the definition of greyscale thresholds for all specimens including  
A) pure calcium phosphate cement and CPC/PLGA composites of B) 90:10, C) 80:20 and D) 70:30 % (w/w). 
Background areas indicated by yellow circles in the exemplary µ-CT slice images represent areas where 
the background greyscale levels were measured. Exemplary greyscale histograms are labelled as 
“background”. The greyscale intervals of those histograms were defined representing the low density 
fractions of the specimens and were measured in triplicates. Consequently, the greyscale interval above 
those histograms determined the threshold for higher density/greyscale intervals which was defined as the 
CPC phase. 
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